Development and clinical translation of microneedles for insulin delivery and self-vaccination by Norman, James Jefferis
DEVELOPMENT AND CLINICAL TRANSLATION OF 

























In Partial Fulfillment 
of the Requirements for the Degree 
Doctor of Philosophy in the 












COPYRIGHT © 2012 JAMES JEFFERIS NORMAN  
DEVELOPMENT AND CLINICAL TRANSLATION OF 


















Approved by:   
   
Dr. Mark Prausnitz, Advisor 
School of Chemical & Biomolecular 
Engineering 
Georgia Institute of Technology 
 Dr. Paula Frew 
Rollins School of Public Health 
School of Medicine 
Emory University 
   
Dr. Mark Allen 
School of Electrical & Computer 
Engineering 
Georgia Institute of Technology 
 Dr. Martin Meltzer 
Office of Infectious Diseases 
National Center for Emerging and 
Zoonotic Infectious Diseases 
Centers for Disease Control and 
Prevention 
   
Dr. Eric Felner 
School of Medicine 
Division of Pediatric Endocrinology 
Emory University 
  
   

































I could not have completed this dissertation without the support of the people 
listed here.  First, I would like to thank my thesis advisor, Dr. Mark Prausnitz for 
accepting me into his world-class research group and advising me for six years.  I was 
quite naïve when I entered the lab, but he took a growth mindset and transformed my 
naïveté into a space for professional growth. 
 As for my other committee members, they each contributed to my education and 
to this dissertation.  Dr. Allen introduced me to graduate research and taught me how to 
ask insightful questions, Dr. Felner introduced me to clinical research, Dr. Frew 
introduced me to the psychological research and participant recruitment, and Dr. Meltzer 
introduced me to life at the CDC and quantitative health economics. 
 Thank you to the graduate students, post-docs, and research scientists I worked 
with in the Prausnitz and Allen groups: Dr. Vladimir Zarnitsyn, Dr. Samir Patel, Dr. 
Saffar Mansoor, Dr. Jyoti Gupta, Chris Edens, Matt Mistilis, Seonhee Park, Dr. Leonard 
Chu, Josh Hutchison, Dr. Sean Sullivan, Dr. Jung-Hwan Park, Dr. Avishek Aiyar, Dr. 
Jason Jiang, Dr. Tanicia Daley, Winston Pewin, Sebastien Henry, Dr. Devin McAllister, 
Dr. Myke Scoggins, Dr. Yeu-Chun Kim, Dr. Hyo-Jick Choi, Dr. Young Bin Choy, Dr. 
Xin Dong Guo, Dr. Seong-O Choi, Dr. Jeong-Woo Lee, Dr. Robyn Schlicher, Dr. Hang 
Jun Park, Dr. Ying Liu, Dr. Samantha Andrews, Dr. Prerona Chakravarty, Dr. Priya 
Kalluri, Aritra Sengupta, Yoo-Chun Kim, Jaya Arya, and Pradnya Samant.  These 30+ 
co-workers are good, helpful friends.  
 v 
Several Georgia Tech staff members helped with this research as well.  Donna 
Bondy deserves the most credit.  She handles a difficult job, yet still has time for 
lighthearted converstations.  Allen Echols, Steve Woodard, James Goddard, and 
Alyceson Andrews managed IBB well.  Richard Shafer helped with laser cutting and 
various other fabrication issues.  Brad Parker, Jeff Andrews, and Dennis Brown 
machined devices for this research.  The PRL staff helped with in vivo studies. Off 
campus, I worked extensively with two suppliers – Andrew Wilt at Permegear and Alan 
Iranian at Cartika – who deserve thanks for meeting deadlines on unusual requests. 
 The following undergraduate researchers put in some significant hours for this 
research: Brian Bondy, Nhien Tong, HyeSun Jun, and Betul Benzer.  I wish them luck in 
the future careers, though I hardly need to. 
 Thank you to Dr. Milton Brown, Nick Raviele, and Alleia Stokes for their roles in 
the insulin study at Emory Children’s Center.  Thank you to Marc Padilla, Marcus 
Bolton, and Brooke Hixson at the Hope Clinic and Dr. Maxine McClain for the help with 
participant recruiting and study conduct.  Thank you to Darin Zehrung, Courtney 
Jarrahian, Emily Griswold, Sarah McGray, Erica Jacoby, and others at PATH for their 
advice and work on the self-administration studies.  Thank you to Dr. Bruce Weniger, 
formerly at the CDC, for sparking my interest in global health.  Thank you to Dr. Alan 
Hinman at Emory University for initially advising the research on self-vaccination. 
Thank you to all of the participants in the research studies.  Thank you to the IRB 
and IACUC for overseeing the responsible conduct of this research. Thank you to the 
funding agencies: the National Institutes of Health, the Thrasher Research Fund, the 
Department of Education, and the Georgia Institute of Technology. 
 vi 
 Thank you to the people outside of work who helped with personal development 
and work-life balance.  Michael Spinner brought out my dedication and ability to finish 
difficult tasks.  Dr. Nelson Binggeli helped me realize my full potential in research.  
Thank you to my family for their love, encouragement, and support.  Lastly, thank you to 

















TABLE OF CONTENTS 
Page 
ACKNOWLEDGEMENTS iv 
LIST OF TABLES xii 
LIST OF FIGURES xiii 
LIST OF SYMBOLS xv 
LIST OF ABBREVIATIONS xvi 
SUMMARY xviii 
CHAPTERS 
1 INTRODUCTION 1 
1.1 Motivation 1 
1.2 Microneedles for Insulin Delivery and Self-Vaccination 2 
1.3 Specific Aims 3 
1.3.1 Fabricate a side-opened, sharp-tipped, hollow metal microneedle 
using micromolding and characterize the microneedles in vitro and 
in vivo 3 
1.3.2 Compare insulin delivery using microneedles and subcutaneous 
catheters in children and adolescents in a phase I randomized trial 3 
1.3.3 Conduct a preliminary human study to evaluate the usability, 
acceptability, and cost-effectiveness of microneedle patches for  
self-vaccination against influenza 3  
1.4 Outline of Remaining Chapters 4 
2 BACKGROUND 5 
2.1 Drug Delivery of Biopharmaceuticals 5 
 2.1.1 Definition of Biopharmaceuticals 5 
 2.1.2 General Unavailability of Oral and Transdermal Delivery 5 
 viii 
 2.1.3 Hypodermic Needle Injections 6 
2.2 The Skin as a Drug Delivery Target for Biopharmaceuticals 7 
 2.2.1 Methods for Transcutaneous Drug Delivery 7 
 2.2.2 Rapid Systemic Uptake and Improved Access to Immune System 8 
2.3 Microneedles 9 
 2.3.1 General Design Criteria for Microneedles 11 
 2.3.1.1 Solid Microneedles 12 
2.3.1.2 Coated Microneedles 12 
2.3.1.3 Dissolving Microneedles 13 
2.3.1.4 Hollow Microneedles 13  
2.4 Insulin Delivery 14 
 2.4.1 Diabetes 14 
 2.4.2 Insulin Therapy for Type 1 Diabetic Patients 15 
 2.4.3 Approved Insulin Administration Methods 16 
2.5 Vaccine Delivery 17 
 2.5.1 Introduction to Vaccines 18 
 2.5.2 Approved Administration Methods 19 
 2.5.3 Vaccination Settings 20 
2.6 Behavioral Analysis with the Theory of Reasoned Action 20 
2.6.1 Method for Generating and Analyzing Data for a Theory 
of Reasoned Action Model 22  
 2.6.2 Example Behavioral Studies Concerning Vaccine Acceptance 23 
2.7 Economic Analysis of Vaccination 23 
 2.7.1 Economic Analysis of Vaccination Devices 26 
3 MOLDING PROCESS FOR HOLLOW METAL MICRONEEDLES 27 
3.1 Introduction 27 
 ix 
3.2 Device Fabrication 28 
 3.2.1 Master Structure 29 
 3.2.2 Replicating the Master Structure 30 
 3.2.3 Seed Layer and Electrodeposition 31 
 3.2.4 Dissolving the Sacrificial Replicate Structure 33 
 3.2.5 Device Assembly 33  
 3.2.6 Final Device Imaging 34  
3.3 Force Displacement Measurement 35 
 3.3.1 Experimental Results 35 
3.4 Insertion and Injection into Pig Skin In Vitro 36 
 3.4.1 Insertion into Pig Skin 36 
 3.4.2 Injection into Pig Skin 37 
3.5 Insertion and Injection into Hairless Guinea Pig Skin In Vivo 37 
 3.5.1 Experimental Results 38 
3.6 Discussion 39 
4 INSULIN DELIVERY USING MICRONEEDLES IN TYPE 1  
DIABETIC CHILDREN AND ADOLESCENTS 43 
4.1 Introduction 43 
4.2 Research Design and Methods 45 
4.3 Results and Discussion 49 
5 USABILITY, ACCEPTABILITY, AND COST-EFFECTIVENESS OF 
MICRONEEDLE PATCHES FOR SELF-VACCINATION AGAINST 
INFLUENZA 58 
5.1 Introduction 58 
5.2 Methods 61 
 5.2.1 Microneedle Patch Fabrication 61 
 x 
 5.2.2 Study Approval and Participant Recruiting 61 
 5.2.3 Experimental Procedures 63 
 5.2.4 Skin Staining to Measure Usability 63  
 5.2.5 Questionnaires to Measure Acceptability 64  
 5.2.6 Quantitative Economic Analysis to Assess  
Cost-Effectiveness 64  
5.3 Results 67 
 5.3.1 Usability 67 
 5.3.2 Acceptability 69 
 5.3.3 Cost-Effectiveness 72 
 5.3.4 Pain 75 
 5.3.5 High Effectiveness Patch: Acceptability and  
Cost-Effectiveness 76  
 5.3.6 Factors Affecting Microneedle Patch Uptake 78  
5.4 Discussion 80 
6 CONCLUSIONS 83 
6.1 Fabrication of Hollow Metal Microneedles 83 
6.2 Insulin Delivery Using Microneedles To Type 1 Diabetic Children 
and Adolescents 83 
6.3 Usability, Acceptability, and Cost-Effectiveness of Microneedle 
Patches for Self-Vaccination against Influenza 84 
7 RECOMMENDATIONS 85 
7.1 Recommendations for Hollow Microneedle Design 85 
6.2 Recommendations for Insulin Delivery to Human Subjects 85 
6.3 Recommendations for Self-Vaccination 86 
6.1 General Recommendations for Microneedles 86 
 
 xi 
APPENDIX A: DETAILED METHODS 89 




LIST OF TABLES 
Page 
Table 3.1: Effect of Starting Condition on Electrodeposition Process Yield 32 
Table 4.1: Participant Demographics (insulin study) 50 
Table 5.1: Participant Demographics (self-vaccination study) 62 
Table 5.2: Inputs of the Economic Model – Illness Parameters and Costs 65 
Table 5.3: Inputs of the Economic Model – Disease Rates 66 




LIST OF FIGURES 
Page 
Figure 2.1: Methods of drug delivery to the skin using microneedles 10 
Figure 2.2: Example image for each type of microneedle 10 
Figure 2.3: Time-action profiles of insulin lispro (Humalog) and regular human 
insulin (Humulin R), both administered subcutaneously 16 
Figure 2.4: Schematic of the theory of reasoned action 21 
Figure 3.1: Fabrication Sequence 29 
Figure 3.2: Optical microscopy images of the microneedle device 34 
Figure 3.3: Representative force-displacement curve for a microneedle pressed  
against a rigid surface 35 
Figure 3.4: Microneedle injection into pig skin in vitro 36 
Figure 3.5: Microneedle injection into hairless guinea pig skin in vivo 39 
Figure 4.1: Microneedle used for intradermal insulin delivery 47 
Figure 4.2: Pain of microneedle and subcutaneous insulin administration 51 
Figure 4.3: Pharmacokinetics and pharmacodynamics of insulin delivery 52 
Figure 4.4: Pharmacokinetic analysis of intradermal insulin delivery using  
microneedles 53 
Figure 5.1: Microneedle patch and examples of skin stains  67 
Figure 5.2: Usability of microneedles versus administration attempt 68 
Figure 5.3: Acceptability of microneedles and self-vaccination 70 
Figure 5.4: Acceptability of microneedles and self-vaccination, equal effectiveness 71 
Figure 5.5: One-way sensitivity analysis for the change in total payer costs after 
introducing self-administered microneedles 73 
Figure 5.5: Two-way sensitivity analysis plotting additional cost for payer to improve 
coverage by 19% 74 
 
 xiv 
Figure 5.7: Paired comparison of pain scores 75 
Figure 5.8: Acceptability of high-effectiveness microneedles and self-vaccination 76 
Figure 5.9: Comparison of cost-effectiveness histograms for different scenarios 76 
  
 xv 
LIST OF SYMBOLS 
 
a  minimum (triangular distribution) 
b  maximum (triangular distribution) 
c  mode (triangular distribution) 
ka  absorption coefficient 
ke  elimination coefficient 
p  probability of a statistical result 
CO2  carbon dioxide 
U  standard unit of insulin 
Δ  delta / change in 
µ  mean (distribution), micro (as a prefix) 
σ  standard deviation  
 xvi 
LIST OF ABBREVIATIONS 
 
ACIP  Advisor Committee on Immunization Practices 
AUC  area under the insulin curve 
BCG  Bacillus Calmette- Guérin vaccine 
BMI  body mass index 
CBA  cost-benefit analysis 
CDC  Centers for Disease Control and Prevention 
CEA  cost-effectiveness analysis 
CI  95% confidence interval 
CSII  continuous subcutaneous insulin infusion 
DALY  disability adjusted life year 
FDA  United States Food and Drug Administration 
GRAS  generally regarded as safe 
HbA1C  glycated hemoglobin 
HCW  healthcare worker 
HIV  human immunodeficiency virus 
IA  investigator administration 
IACUC  institutional animal care and use committee 
IM  intramuscular 
IRB  institutional review board 
LAIV  live attenuated influenza vaccine 
LED  light-emitting diode 
MN  microneedle 
MNs  microneedles 
 xvii 
NPH  neutral protamine Hagedorn 
OR  odds ratio 
PBS  phosphate buffered saline 
PDMS  poly(dimethylsioxane) 
PLA  poly(lactic acid) 
QALY  quality adjusted life year 
SA  self-administration 
SC  subcutaneous 
SIC  subcutaneous infusion catheter 
US  United States 
VAS  visual analog scale 




Type 1 diabetes and influenza cause significant illness and unnecessary medical 
costs despite the existence of insulin for maintenance of diabetes and a vaccine for 
prevention of influenza.  This dissertation describes three studies on the development and 
clinical translation of microneedles to improve the administration of these 
biopharmaceuticals. 
The first study reports on a sharp-tipped hollow metal microneedle designed to 
reduce manufacturing costs, improve insertion into skin, and improve fluid flow 
compared to other hollow microneedles used for drug delivery.  The results showed 
sharp-tipped metal microneedles could be fabricated using an inexpensive electroplating 
and sacrificial micromolding process.  Single-microneedle devices made by this method 
achieved high flow rates and delivered model drugs into tissue. 
The second study reports on insulin delivery using microneedles in children with 
type 1 diabetes.  The results showed microneedle insertion was less painful, which is a 
promising result for improving injection compliance in children.  Additionally, 
microneedle delivery showed rapid onset of insulin action compared to subcutaneous 
catheter delivery, which may enable automatic closed-loop insulin therapy. This was the 
first study of drug delivery to children using microneedles.  
The last study reports on microneedle patches for self-vaccination against 
influenza.  Human subjects were recruited from greater Atlanta, were asked to self-
administer placebo microneedle patches, and were then given a dynamic questionnaire to 
determine their views and preferences regarding influenza vaccination using 
 xix 
microneedles compared to conventional intramuscular injection. The results showed that 
microneedles were usable by the participants, the introduction of microneedles may 
improve vaccination coverage by approximately 20%, and self-administration of vaccines 
may significantly reduce vaccination costs for a healthcare payer. This was the first study 
to assess the ability of human subjects to self- administer a microneedle patch and the 
first study to determine the potential impact of self-vaccination against influenza using a 
microneedle patch on vaccination coverage and vaccination cost.  
Overall, the fabrication advances and positive findings from human subjects 
research support additional translation of microneedles for insulin delivery and self-








Insulin and influenza vaccines have been administered to millions of patients over 
several decades, but for both these important medicines, significant delivery challenges 
remain. 
 For insulin delivery to type 1 diabetic patients, the challenge is twofold.  First, 
many patients fear injections and this fear of injection correlates with worse glycemic 
control and health outcomes [1-3].  Second, insulin uptake after subcutaneous delivery is 
too slow to enable automated control of blood glucose [4], leaving patients with the 
significant responsibility for monitoring and managing their diabetes. 
For influenza vaccination, the challenge is improving vaccination coverage while 
constraining costs.  The United States has a universal influenza vaccination 
recommendation, but coverage levels fall well below target due to reasons such as 
injection phobia and inconvenience of vaccinations [5].  As a result, the United States has 
more than 200,000 hospitalizations and 3,000-49,000 deaths due to influenza each year 
[6].  Expanding influenza coverage is desirable but brings cost-effectiveness concerns, 
particularly for healthy adults age 18-49, the last group recommended for influenza 
vaccination.  The cost effectiveness of influenza vaccine delivery is primarily limited by 




1.2 Microneedles for Insulin Delivery and Self-Vaccination 
 Microneedles, needles less than 1.5 mm in length used for skin delivery of drugs, 
may help solve the challenges of insulin and influenza vaccine delivery.  Drugs such as 
insulin and influenza vaccines, normally impermeable in skin, can be precisely injected 
as liquids using hollow microneedles or as solids with coated or dissolving microneedles 
[8]. 
 For insulin delivery, microneedles are expected to reduce injection fear because 
the needles are barely perceptible.  Additionally, microneedle trials completed to date 
have shown microneedles consistently reduce needle-insertion pain compared to 
traditional injection methods [9].  Studies in adults have also shown that microneedle-
mediated intradermal delivery accelerates insulin pharmacokinetics [10, 11], potentially 
enabling closed-loop control of blood glucose. 
 Microneedles may benefit influenza vaccination not just by reducing needle-
phobia, but also by enabling self-administration of vaccines.  Currently, only one self-
administered vaccine exists, the oral typhoid vaccine [12].  Using microneedles to expand 
self-vaccination to the more commonly used influenza vaccine could improve 




1.3 Specific Aims 
1.3.1 Fabricate a side-opened, sharp-tipped, hollow metal microneedle using 
micromolding and characterize the microneedles in vitro and in vivo 
 The purpose of this study was to integrate several desirable features of hollow 
microneedles into a single design with a simple manufacturing process. The resulting 
microneedles were characterized with destructive testing as well as fluorescent dye 
delivery in pig and hairless guinea pig skin. 
1.3.2 Compare insulin delivery using microneedles and subcutaneous catheters in 
children and adolescents in a phase I randomized trial 
 To improve children’s compliance with insulin therapy and accelerate insulin 
pharmacokinetics, this study tested the hypothesis that intradermal insulin delivery using 
microneedles causes less insertion and infusion pain and leads to faster onset (time to 
peak concentration) and offset (time to fall to half of peak concentration) of insulin 
pharmacokinetics in children with type 1 diabetes compared to conventional 
subcutaneous injection.  In this repeated measures study, 16 pediatric type 1 diabetic 
patients participated and experienced microneedle and subcutaneous administration of 
insulin on separate days.  
1.3.3 Conduct a preliminary human study to evaluate the usability, acceptability, and 
cost-effectiveness of microneedle patches for self-vaccination against influenza 
 We conducted a randomized, repeated measures trial to assess whether a 
self-administered microneedle patch is usable, acceptable, and more cost-effective for 
improving vaccination coverage compared to intramuscular injection. Seventy healthy 
adults experienced three self-administrations, one investigator-administration, and a 
 4 
control intramuscular injection. We measured usability with skin staining and 
acceptability with a stated preference questionnaire. A quantitative economic model 
evaluated cost-effectiveness in terms of additional payer costs needed to improve 
vaccination coverage.  Prior to this study, there were no data on self-vaccination using 
microneedle patches and limited information comparing self-administration to healthcare-
worker-administration for other vaccination methods [13-15], but no studies assessing 
coverage improvements due to self-administration or cost-effectiveness for equivalent 
vaccines. 
1.4 Outline of Remaining Chapters 
Chapter 2 contains background reading on microneedles, the drug delivery 
problems motivating this work, and the methods used in this dissertation; chapters 3-5 
present work done on the three specific aims; chapter 6 concludes the dissertation; 






2.1 Drug Delivery of Biopharmaceuticals 
2.1.1 Definition of Biopharmaceuticals 
Biopharmaceutical, as a term, has several meanings.  This dissertation will use the 
following recommended definition: a biopharmaceutical is “a pharmaceutical inherently 
biological in nature and manufactured using biotechnology” [16].  Biopharmaceuticals 
include proteins, polysaccharides, nucleic acid chains, as well as larger structures such as 
viruses and bacteria. 
2.1.2 General Unavailability of Oral and Transdermal Delivery 
 Oral delivery and transdermal patch delivery are two well-accepted, low-cost 
means of delivering drugs.  The oral route is unavailable for most biopharmaceuticals due 
to degradation in the gastrointestinal tract or limited systemic uptake [17].  Current 
exceptions are rare and include small cyclic proteins [18], vaccines targeted against orally 
transmitted pathogens (polio, typhoid, cholera, and rotavirus), and one oral adenovirus 
vaccine [19]. 
 Delivery of drugs across intact skin using transdermal patches is also unavailable 
for most biopharmaceuticals because of drug size restrictions.  The uppermost layer of 
skin, a 15µm layer called the stratum corneum, is a diffusion barrier that prevents water 
loss and entry of foreign molecules.  Drug delivery across the stratum corneum is limited 
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to small, lipophilic compounds that can diffuse through the lipid bilayers of the barrier’s 
cells [20, 21].    Drugs amenable to transdermal delivery are all less than 500 Da in 
molecular weight and approximately 1 nm in diameter [22].  Typical biopharmaceuticals 
are much larger.  Insulin has a molecular weight of approximately 6000 Da, depending on 
the specific amino acids.  Influenza vaccines range from single proteins with molecular 
weights of 56,000 Da [23] to whole viruses 100 nm in diameter.  These large 
biopharmaceuticals are unable to cross an intact diffusion barrier of the skin for 
significant therapeutic effect. 
2.1.3 Hypodermic Needle Injections 
 Because the oral and transdermal routes are unavailable, the majority of 
biopharmaceuticals are administered by injection with a hypodermic needle.  As 
mentioned in [8], “[injections provide] a low-cost, rapid, and direct way to deliver almost 
any type of molecule into the body.”  Drugs can be injected into numerous tissues, but the 
most common injections for biopharmaceuticals are subcutaneous and intramuscular 
injections.  The subcutaneous space is the fat layer below the skin, and it is a common 
injection site for insulin [24] and vaccines [25].  Intramuscular injections deliver fluid to 
muscles below the subcutaneous space.  Inactivated influenza vaccines are traditionally 
given intramuscularly [25].  Another, less common administration route is intradermal 
injection, injection of fluid into the skin.  Intradermal injections are used to administer 
certain biopharmaceuticals such as tuberculin and the rabies vaccine [26].  Intradermal 
injections using hypodermic needles are uncommon because they require shallow, angled 
injections that are difficult to perform [27]. 
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 Injections, although widely used, have limitations.  These include: 1) pain and 
fear that reduce patient compliance [1, 28], 2) the restrictions on self-administration due 
to the need for patient training and safe needle disposal, and 3) the difficulty targeting 
drugs anywhere except deep into a tissue. 
2.2 The Skin as a Drug Delivery Target for Biopharmaceuticals 
Several new drug delivery techniques are in development to replace hypodermic 
needle injections for delivery of large biopharmaceuticals.  Drug delivery to the skin, also 
known as transcutaneous delivery, overcomes the limitations of hypodermic needle 
injections:  1) patients mostly perceive skin delivery methods as less painful than 
injections [21, 29]; 2) skin delivery methods may enable safe self-administration of 
biopharmaceuticals [21, 29]; and, 3) skin delivery enables targeting to the circulatory 
system for rapid drug uptake and the immune system for improved immunotherapeutics. 
2.2.1 Methods for Transcutaneous Drug Delivery 
 A review of transcutaneous drug delivery methods is available from Kim et al. 
[29]. Traditional techniques for drug delivery to the skin include intradermal delivery 
[27] (see section 2.1.3) and scarification.  Scarification involves poking a liquid 
formulation into the skin with a short needle like a bifurcated needle [30].  Modern 
techniques project a drug into the skin, inject a drug into the skin, or modify skin 
permeability to enable patch delivery of biopharmaceuticals.  Projectile methods include 
jet injection [31] and gene gun delivery [32].  Injection methods include tattoo gun 
delivery [33]  and delivery with coated, dissolving, and hollow microneedles [34].  
Methods for modifying skin permeability for patch application of biopharmaceuticals 
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include solid microneedle application [35], skin abrasion [36], ultrasound [37], 
electroporation [38], chemical enhancers [39], and thermal ablation [40].  This 
dissertation focuses primarily on microneedles, and the rationale for using microneedles 
over other skin delivery techniques is discussed in section 2.3. 
2.2.2 Rapid Systemic Uptake and Improved Access to the Immune System 
 Biopharmaceuticals administered to the skin, including insulin [10, 11, 41, 42], 
parathyroid hormone [43], and etanercept [44], have shown rapid systemic uptake (rapid 
pharmacokinetics) compared to traditional injection methods such as subcutaneous 
delivery.  The vascular and lymphatic networks in the skin are higher in density and more 
permeable compared to the vascular and lymphatic networks in the subcutaneous space 
[45, 46].  It is hypothesized that large biopharmaceuticals have enhanced 
pharmacokinetics due to rapid lymphatic uptake [44].  Whether the rapid uptake is 
beneficial for a biopharmaceutical’s action in the body, its pharmacodynamics, depends 
on the drug. 
 In addition to enhanced pharmacokinetics, the skin also provides enhanced access 
to the immune system compared to other injection sites [44, 47, 48].  For vaccines in 
particular, skin immunization can lead to improved immune responses (ex: improved 
antibody titers, memory, or cross-protection) at equal doses [49-51] or equivalent 
immune responses at reduced doses [52-54].  The improved vaccine responses are 
thought to result from efficient targeting of antigen presenting cells prevalent in the skin.  




Microneedles are needles reduced to the micron scale. The smallest needle 
available for hypodermic injection is 4 mm long [56], whereas microneedles range from 
100 µm to 1.5 mm in length [57, 58]. The core concept of microneedles is that these 
small needles minimally penetrate past biological diffusion barriers for targeted drug 
delivery.  Examples include: 1) passing the outer layer of the skin, the stratum corneum, 
for drug delivery to the skin [59], 2) passing the outer layer, the sclera, for drug delivery 
to the back of the eye [60], and passing cell membranes for drug delivery to cells [61].  
Transcutaneous drug delivery was the first clinical application considered for 
microneedles [62, 63] and remains the predominant application of microneedles today [8, 
9].  In pre-clinical and clinical studies, microneedles have delivered  hormones [10, 11, 
43], vaccines [64], nucleic acid chains [65], and other biopharmaceuticals to the skin. 
There are generally four types of microneedles: 1) solid microneedles, 2) coated 
microneedles, 3) dissolving microneedles, and 4) hollow microneedles [8].  Figure 2.1 
shows the method of drug delivery to the skin for each type of microneedle.  Figure 2.2 
shows an example image of each type of microneedle. 
Microneedles have advantages over other transcutaneous drug delivery methods.  
The solid-state microneedles (solid, coated, and dissolving microneedles) are 
conceptually inexpensive and easy to use [8, 26] with limited dose variability, a concern 
with delivery via the mucosal route [66].  Hollow microneedles offer the highest degree 
of control over drug delivery rate for any transcutaneous method and may eliminate the 
need for drug reformulation [67]. 
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Figure 2.1.  Methods of drug delivery to the skin using microneedles (MN). Microneedles 
insert into the skin (A) and then deliver drugs (B).  Solid microneedles pretreat the skin, 
after which a topical formulation is applied that diffuses through the open pores.  Coated 
microneedles deliver a coating of drugs that dissolves in the skin.  Dissolving 
microneedles contain drugs in a composite matrix that dissolves in the skin, leaving no 




Figure 2.2.  Example image for each type of microneedle: a) solid microneedles, each 
microneedle is 750 µm long (credit: Gary Meek, Georgia Tech), b) coated microneedles, 
each microneedle is 750 µm long (credit: Harvinder Gill, Georgia Tech), c) dissolving 
microneedles, each microneedle is 650 µm long (credit: Sean Sullivan, Georgia Tech), d) 
hollow microneedle, 850 µm long (credit: Gary Meek, Georgia Tech) 
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2.3.1 General Design Criteria for Microneedles 
The different types of microneedles have similar design considerations.  The 
choice of length depends on the target tissue and the drug delivery requirements, but 
microneedles are generally 1.5 mm or less in length for targeting purposes and pain 
minimization.  Concerning needle number, solid, coated, and dissolving microneedles 
have a larger drug delivery capability in an array format (e.g., a 10x10 array of 100 
microneedles) [8].  However, single hollow microneedles are often sufficient, as the 
amount delivered is not constrained by needle size or number [67].   
Sharp tips are necessary to facilitate insertion into tissue [68-70].  This mandates 
some kind of taper in a microneedle’s geometry, either from the base up as with conical 
and pyramidal geometries (Fig 2.2C) or from a higher-up point (Figure 2.2 A,B,&D).  
The geometry away from the tip matters for insertion depth, as slender microneedle 
designs [71] will insert deeper than tapered designs with low aspect ratios [72].  Material 
choice is constrained to biocompatible materials or generally-regarded-as-safe (GRAS) 
materials approvable by the FDA, e.g., for parenteral injection.  Mechanical failure of 
microneedles is a concern given their small size and constraints on material choice.  A 
common guideline in the literature for preventing mechanical failure of microneedles is 
that the insertion force for a particular microneedle must be much less than its critical 
buckling load [68, 70, 73], although microneedles can fail due to non-axial forces as well. 
Microneedles can be inserted into skin manually, by applying pressure with a 
thumb, or automatically, with the help of a mechanical applicator.  Applicators help with 
microneedle insertion by consistently applying the correct amount of force for insertion, 
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but they also add expense.  Applicators that apply microneedles at high speed limit the 
skin deformation that occurs during manual microneedle administrations.  A summary of 
microneedle applicators is available in [74]. 
2.3.1.1 Solid Microneedles 
 As shown in Figure 2.1, solid microneedles create pores in the skin for enhanced 
drug transport. The main function of a solid microneedle is to insert into the tissue with 
minimal pain and survive the process without breaking.  Solid microneedles are typically 
made of stiff materials (materials with high elastic moduli: metals, silicon, ceramics) to 
maximize microneedle robustness while minimizing microneedle size [8].  Fabrication 
methods include laser cutting, injection molding, and various etching processes [8]. 
2.3.1.2 Coated Microneedles 
 Coated microneedles are essentially solid microneedles coated with a drug 
formulation so that upon insertion, the coating inserts with the microneedles and 
dissolves in the tissue.  Co-localizing the drug onto microneedles limits the potential 
amount delivered, but simplifies administration compared to solid microneedles by 
eliminating the need for an external drug source [75].  Coating formulations often contain 
viscosity enhancers, surfactants and chemical stabilizers alongside drugs to enhance the 
amount coated, to obtain a uniform coating, and to protect the drugs’ stability after drying 
[8].  Coating methods include dip coating [75], spray coating [76], and layer-by-layer 
coating [77].  Coated drugs in a solid state can have enhanced thermostability compared 
to drugs kept in a liquid state [78, 79].  The enhanced thermostability could obviate the 
need for a cold chain for vaccine distribution. 
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2.3.1.3 Dissolving Microneedles 
 Dissolving microneedles are an extension of coated microneedles where the entire 
microneedle dissolves in the skin as opposed to just a coating.  The key advantage is that 
dissolving microneedles, after use, should not constitute sharps waste and pose little-to-
no risk of needlestick injury because the needles have dissolved [80].  Drugs in 
dissolving microneedles can also have enhanced thermostability [81].   
 One drawback of dissolving microneedles is that the strongest available 
dissolving materials are approximately 100-times less stiff than non-dissolving materials 
used for solid microneedles.  To resolve this issue, dissolving microneedles have broader 
bases compared to solid microneedles to increase the critical buckling load [68, 72].  
These large, low-aspect-ratio microneedles have two complications: 1) typically, only 
half of the microneedle length inserts into tissue and 2) the larger microneedles take 
longer to dissolve in skin, e.g., > 5 minutes, depending on design. Separable “arrowhead” 
microneedles posted on metal shafts overcome these issues by increasing the functional 
microneedle length and depositing the dissolving arrowhead in the skin to dissolve [82].  
Dissolving microneedles have been made out of natural and synthetic polymers using 
micromolding and drawing techniques [8]. 
2.3.1.4 Hollow Microneedles 
 Whereas other microneedle types rely on passive diffusion of drugs, hollow 
microneedles inject drugs using pressure-driven fluid flow, much like a hypodermic 
needle injection.  The advantages of hollow microneedles compared to passive delivery 
methods are: 1) faster delivery; 2) greater control over delivery rate, especially in 
conjunction with an electric pump [67]; 3) larger delivery capability because the amount 
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delivered is not constrained by microneedle size; and, 4) no need for reformulation of 
drugs [67].  Reducing hollow needles to the micron scale has many challenges, though: 1) 
fabrication is inherently more difficult and costly compared to non-hollow microneedles, 
2) the hollow interior reduces the critical failure load and makes hollow microneedles 
more fragile upon insertion, 3) integrating with a pressure source after fabrication adds 
additional complexity, 4) leaks are a concern because hollow microneedles do not insert 
very deep into tissue, and 5) the small lumens on hollow microneedles can become sealed 
by tissue requiring them to be offset from center [69, 83].  Researchers have made hollow 
microneedles out of glass, photolithographic materials, silicon, plastics, and metal [8].  
Several techniques have been used to fabricate hollow microneedles: 
microelectromechanical systems (MEMS) techniques, laser machining, bevel grinding, 
hot embossing, injection molding, and electrodeposition onto sacrificial molds  [8].  
2.4 Insulin Delivery 
2.4.1 Diabetes 
 Diabetes, also known as diabetes mellitus, is a chronic disease characterized by 
abnormally high concentrations of glucose in the blood [84].  Glucose accumulation in 
diabetes stems from problems with insulin production or insulin resistance.  Insulin is a 
peptide hormone that regulates carbohydrate and fat metabolism.  One critical function of 
insulin is to induce cells to uptake glucose. When this process fails, diabetes occurs. 
 Several types of diabetes exist.  Type 1 diabetes mellitus results from destruction 
of a patient’s insulin secreting cells (pancreatic islet β cells) with patients prone to a 
secondary fat metabolism disorder called ketoacidosis.  The majority of type 1 diabetes 
 15 
cases are caused by autoimmune destruction of the β cells (type 1A), but 10% of cases 
are idiopathic (type 1B).  Approximately one million people in the United States have 
Type 1 diabetes.  Type 2 diabetes results insulin resistance, reduced sensitivity of the 
cellular glucose uptake mechanism, combined with defects in insulin secretion.  Type-2 
diabetes accounts for 90-95% of diabetes cases in adults in the United States [85].  A 
small number of other diabetes cases result from pregnancy, genetic disorders, chemical 
toxicity, and other endocrine diseases.  
2.4.2 Insulin Therapy for Type 1 Diabetic Patients 
 The insulin delivery work in this thesis focuses on insulin delivery for type 1 
diabetic patients.  Type 1 diabetic patients require insulin therapy, but the majority of 
type 2 diabetic patients do not [85].  Insulin therapy for type 1 diabetic patients has two 
components: bolus delivery and basal delivery [84].  Bolus insulin delivery is delivery of 
insulin over a short time frame to account for the expected rise in blood glucose after a 
meal.  Basal delivery of insulin mimics natural delivery of a small amount of insulin to 
account for insulin needs in basal metabolic processes. 
 Different types of insulin are available with unique amino acid sequences and 
pharmacokinetic profiles.  Regular human insulin mimics insulin naturally produced by 
human β cells and has a peak insulin concentration in the blood 2-3 hours after injection 
(see Figure 2.3).  NPH insulin, an intermediate-acting insulin, has a slightly slower onset.  
Fast-acting insulins (lispro, aspart, and glulisine) have faster onset times than regular 
human insulin and provide improved glycemic control for bolus delivery [86].  Faster 
acting insulin analogs are in development to mimic the insulin release kinetics from β 
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cells [87].  The action of current insulin analogs is too slow to allow automatic control of 
blood glucose, so patients must plan each insulin injection and monitor their blood 
glucose afterwards.  Ultra-fast-acting insulins could enable automatic control of blood 
glucose, also known as closed-loop insulin therapy [88]. 
 
 
Figure 2.3. Time-action profiles of insulin lispro (Humalog) and regular human insulin 
(Humulin R), both administered subcutaneously.  Insulin lispro is faster acting compared 
to regular human insulin (figure from Humalog package insert, Eli Lilly & Co.) 
   
2.4.3 Approved Insulin Administration Methods 
 All current insulin formulations approved for use in the United States are 
administered subcutaneously by injection with a needle and syringe [84].  An inhalable 
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insulin formulation was available briefly but taken off the market due to poor sales [89].  
Jet injection is available but not recommended for routine use [24]. 
Two common methods of administering insulin include: 1) a daily injection of a long-
acting insulin with bolus injections of regular- or fast-acting insulin for each meal and 2) 
continuous subcutaneous insulin infusion (CSII) using a programmable electronic pump.  
CSII uses the same insulin formulation, often a fast-acting insulin, for continuous basal 
insulin infusion and programmed bolus infusions for each meal.  The pumps administer 
insulin through a subcutaneous infusion catheter (SIC) which patients insert with a 
spring-loaded hypodermic needle. 
  2.5 Vaccine Delivery 
2.5.1 Introduction to Vaccines 
 Vaccines provide protective immunity against infectious disease before a natural 
infection occurs [55].  In the United States, vaccines are available to protect against over 
25 distinct viral and bacterial pathogens [90].  Different types of antigens are used as 
vaccines: attenuated live pathogens, inactivated pathogens, purified surface components 
of pathogens, toxins produced by pathogens, and toxins covalently bonded to other 
antigens.  Vaccines are sometimes delivered with adjuvants, such as aluminum salts that 
improve immune responses through multiple mechanisms such as controlled release of an 
antigen and enhanced uptake by antigen-presenting cells [91]. 
Part of this dissertation focuses on seasonal influenza vaccine delivery.  Seasonal 
influenza is a viral respiratory disease with sufficient antigenic drift to cause yearly 
epidemics in the fall and winter [92].  This differs from pandemic influenza outbreaks 
that result from large, infrequent antigenic shits.  Most current influenza vaccines are 
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split vaccines, i.e., influenza viruses split into a mix of constituent parts, or subunit 
vaccines composed of purified influenza virus surface proteins [93].  These vaccines are 
injected either intramuscularly or intradermally.  A live-attenuated influenza vaccine 
(LAIV) is available for nasal administration with approximately 10% market share 
overall [94] and a one-third market share in children [95].  Seasonal influenza vaccines 
contain three distinct antigens to account for multiple possible co-circulating strains [92] 
Beginning in 2010, the Advisory Committee on Immunization Practices (ACIP) 
of the United States recommended universal seasonal influenza vaccination for all people 
above six months in age, expect for those contraindicated against the vaccine [25].  
Children under nine years of age receiving their first seasonal influenza administration 
receive two doses.  All others receive one dose.  People who are moderately or severely 
ill are contraindicated against receiving the vaccine.  Those who have life-threatening 
allergies, have had severe reactions to an influenza vaccine, or have had Guillain-Barré 
syndrome are expected to consult with a doctor before receiving a vaccine [96]. The 
seasonal influenza vaccination coverage (the percentage of recommended people who 
receive the seasonal influenza vaccine) in 2011-2012 was 45.5 ± 1.5% [5], well below 
targeted levels.      
One vaccination concept important for this dissertation is vaccine efficacy.  From 
[92], “vaccine efficacy is the percentage reduction in disease incidence attributable to 
vaccination.”  When the reduction in disease incidence is measured in a prospective 
randomized, controlled trial, the term vaccine efficacy is used.  If the observation of 
disease reduction is retrospective, the term vaccine effectiveness is used.   
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The effectiveness of seasonal influenza vaccines is limited by vaccine 
composition and antigenic drift.  Inactivated influenza vaccines lack immunogenicity [93, 
97], and newer vaccines and formulations are expected to offer improved effectiveness.  
LAIV offers improved effectiveness in children, but evidence is mixed for adults [98].  
Studies to assess the effectiveness of a high dose inactivated influenza vaccine are 
ongoing [99].  Intradermal injection offers equal efficacy at reduced and equal doses 
compared to intramuscularly injected influenza vaccines [100].  Newer skin 
immunization methods, including coated and dissolving microneedles, have not been 
evaluated for efficacy or effectiveness in humans.  Efficacy improvements after 
microneedle immunization are hypothesized, based on animal data [64].  
 
2.5.2 Approved Administration Methods  
 The majority of vaccines are administered intramuscularly or subcutaneously 
[101].  The intramuscular route is used for most inactivated vaccines including 
inactivated influenza vaccines.  The subcutaneous route is used for certain live-attenuated 
vaccines: measles, mumps, rubella, and varicella-based vaccines.   
 In the United States, the FDA and ACIP have approved eight vaccines for 
alternative administration routes: oral rotavirus vaccine, oral adenovirus vaccine, oral 
typhoid vaccine, intranasal LAIV, intradermal inactivated influenza vaccine, intradermal 
Bacillus Calmette-Guérin (BCG) vaccine, intradermal rabies vaccine, and smallpox 
vaccine administered with a bifurcated needle [25, 90].  The WHO has prequalified two 
other vaccines for alternative administration in international use: oral polio vaccine and 
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oral cholera vaccine [102].  Several new methods for administering vaccines are in 
development, including microneedles [8, 47, 66, 103-106]. 
  
2.5.3 Vaccination Settings 
 In the United States, routine immunizations are given in multiple settings: 
traditional healthcare settings, pharmacies, mass vaccination sites, and patients’ homes 
[7, 101].  The traditional healthcare settings (doctors’ offices, clinics, and hospitals) are 
the primary location for all childhood and adult immunizations.  The pharmacy setting is 
used for vaccinations in all 50 states, primarily for adult vaccinations [107]. Mass 
vaccination sites include work sites, town halls, and schools.  Vaccination at home is only 
available for the oral typhoid vaccine in the United States. For influenza vaccination in 
2012, 57% of vaccinations were given in traditional healthcare settings, 20% in 
pharmacies, and 23% at mass vaccination sites [5].  Other vaccination settings are used 
for hard-to-reach populations in developing countries or for non-routine immunizations to 
stop outbreaks or pandemics [108]. 
 
  2.6 Behavioral Analysis with the Theory of Reasoned Action 
 This dissertation includes a behavioral analysis based on the theory of reasoned 
action to explore determinants of people’s choice between a microneedle patch and an 
intramuscular injection for influenza vaccination.  Icek Ajzen and Martin Fishbein 
introduced the theory of reasoned action in 1967 as a universal theoretical model for 
predicting behavior [109].  Their description of the model follows, and a schematic of the 
model is shown in Figure 2.4.   
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“According to the theory of reasoned action, a person’s intention is a 
function of two basic determinants, one personal in nature, and the other 
reflecting social influence.  The personal factor is the individual’s positive 
or negative evaluation of performing the behavior; this factor is termed 
attitude towards the behavior.  … The second determinant of intention is 
the person’s perception of the social pressures put on him to perform or 
not perform the behavior in question.  Since it deals with perceived 
perceptions, this factor is termed subjective norm. … Generally speaking, 
individuals will intend to perform a behavior when they evaluate it 




Figure 2.4. Schematic of the theory of reasoned action [109]. 
 
A meta-analysis of studies based on the theory of reasoned action illustrates the 
utility of this behavioral model. “Not only does the model appear to predict consumer 
intentions and behavior quite well, it also provides a relatively simple basis for 
identifying where and how to target consumers' behavioral change attempts” [110].  The 
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meta-analysis also found that while Fishbein and Ajzen intended to model only single 
behaviors, the theory performs well for modeling choices of behaviors.  Examples of 
choices of behaviors would include whether to receive a vaccine and whether to choose a 
particular device for a vaccination. 
Alternatives to the theory of reasoned action include the theory of planned 
behavior [111], a modification that includes perceived behavioral control as a factor 
affecting intent, and the health belief model [112], a predictive model of health behavior 
based on perceived susceptibility, severity, barriers, and benefits. 
2.6.1 Methods for Generating and Analyzing Data for a Theory of Reasoned Action 
Model 
 This dissertation focuses on modeling intent using the theory of reasoned action.  
Modeling this case requires measurements of intent as well as measurements of the 
individual constructs [109]. 
  A behavior needs to correspond to a specific action acting on a specific target 
within a given time and context.  An example of a behavior is receiving an influenza 
vaccine within the next year at a patient’s preferred location (e.g. doctor’s office or 
pharmacy).  Intent to perform that behavior can be measured in several ways: a yes/no-
binary measure, a measure of percent likelihood to perform that behavior, or a scale 
based measure (e.g. from 0-10 likelihood).  Differential intents, differences between 
likelihoods, can be used to model a choice between two behaviors. 
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 The individual constructs, such as attitudes or subjective norms, are typically 
measured using scales consisting of a series of questions.  The topics addressed in the 
constructs are difficult to assess with a single question.  A scale provides a way to 
measure multiple aspects of a construct and condense it into a single measurement [113].  
When multiple scales are measured using the same questionnaire, factor analysis can be 
performed to ascertain whether the scales are distinct from one another as factors and 
whether the scales have adequate internal consistency [114, 115].  Factor analysis 
produces orthogonal, independent scales that can serve as variables for modeling 
behavioral intent. 
2.6.2 Example Behavioral Studies Concerning Vaccine Acceptance 
 Behavioral models have characterized factors affecting vaccine acceptance.  
Example studies include models for acceptance of influenza vaccines [116-119], human 
papillomavirus vaccines [115, 120-124], pneumococcal vaccines [125, 126], hepatitis B 
vaccines [127], and hypothetical vaccines against HIV or gonorrhea [128-130].  For 
influenza vaccination in adults, studies show that the attitude towards vaccination is a 
stronger predictor of vaccination acceptance than subjective norms.  
  2.7 Economic Analysis of Vaccination 
 New vaccines or vaccination devices may offer a variety of healthcare benefits 
such as prevention of disease or reduced administration costs.  However, newer vaccines 
and devices add healthcare costs, especially when replacing existing off-patent, mass-
produced alternatives [131].  A general research question for a vaccine-related economic 
analysis is whether the improved benefit is “worth” the increased cost.  Answering this 
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question can help determine how a new vaccine or device should be priced [132].  The 
worth is subjective and depends on perspective, timeframe, and the health outcome 
considered. 
 A variety of perspectives are available for economic analyses of vaccination, and 
the choice of perspective affects which costs and benefits are included in the analysis 
[133].  For example, patients may prefer self-administering a vaccine because they do not 
have to wait to receive a vaccine.  However, a healthcare payer (an agency providing 
health insurance or health benefits) is only concerned about the cost of delivering a 
service and would not include patient time in an economic analysis of a new device.  For 
analyses presented to government agencies, the societal perspective, encompassing all 
possible costs and benefits, is the preferred perspective [131, 134].  The healthcare 
payer’s perspective is a useful alternative for devices for adult vaccinations, since 
healthcare payers are likely the primary purchasers of the devices. 
 Because the benefits of a vaccine may not accrue until several years after 
vaccination (e.g. liver cancer prevention after hepatitis B vaccination), the timeframe and 
the method for valuing future costs and benefits are important considerations for an 
economic analysis [131, 133].  Most of the costs and benefits of influenza vaccination 
occur within one year, so the timeframe for economic analyses of influenza vaccinations 
typically use a 1-year timeframe with no discounting of future benefits [7]. 
 Different types of economic analyses exist for different outcome measures [131, 
133].  A cost benefit analysis (CBA) assesses whether the benefits (in units of currency) 
of a new vaccine or device outweigh the costs.  The drawback of CBA is that it is 
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difficult to convert some vaccination benefits, like reduced deaths, to units of currency.  
A cost effectiveness analysis (CEA) assesses costs in terms of prevented health 
outcomes.  CEA is useful for comparing two similar interventions that result in the same 
prevented health outcomes.  Cost utility analysis assesses costs in terms of standardized 
health metrics such as quality adjusted life years (QALYs) or disability adjusted life 
years (DALYs).  Cost utility analyses enable comparisons of disparate health 
interventions on equal terms, but QALYs and DALYs are subjectively measured and the 
measurement methodology is controversial [135, 136]. 
 Economic analyses tend to be prospective and rely on assumptions and uncertain 
inputs. Even after well-done investigations, some additional information is needed to 
answer specific economic questions [133].  Economists use mathematical models to fill 
in the missing information.  In a mathematical model, assumptions can be varied to see 
the effect on cost-effectiveness, and uncertain inputs can be sampled repeatedly from 
random distributions to generate confidence intervals and most-likely values for outputs.  
Some mathematical models can also be used to study the dynamics of disease 
transmission for different interventions [137].  Sensitivity analyses of mathematical 
models allow modelers to find what parameters affect the output most.  If the output is 
significantly affected by an assumption of a measurable variable (e.g. patient waiting 
time for vaccination), this suggests further research in measuring that variable to reduce 




2.7.1 Economic Analysis of Vaccination Devices 
 Economic analyses of vaccination devices have been performed to examine the 
tradeoff between increased device costs and several factors: improved safety compared to 
standard injections [138-140]; dose sparing due to alternative delivery routes [105, 140, 
141]; reduced administration costs [105, 139], reduced waste [140, 142], improved 
effectiveness [143], and reduced number of doses needed [140].  Self-administration of 
vaccines may constitute a new way to reduce administration costs.  In addition, a new 
factor to consider for devices is the ratio of patients who prefer self-administration to 
healthcare-worker-administration when both options may be available.  This will affect 
the cost-effectiveness because the weighted-average administration cost will drop as 




MOLDING PROCESS FOR HOLLOW METAL MICRONEEDLES 
 
3.1 Introduction 
Intradermal injection has pharmacological benefits over alternative injection 
methods for various different drug delivery scenarios.  For vaccines, injection into the 
skin enables dose sparing and increased immunogenicity [29, 140].  For dermatological 
medicines, intradermal delivery targets drugs to the site of action in the skin with higher 
bioavailability than topical application [144].  Newer applications of intradermal 
injection include improved lymphatic uptake of etanercept to treat autoimmune diseases 
like rheumatoid arthritis [44] and expedited pharmacokinetics of insulin delivery to 
improve treatment of diabetes mellitus [10, 11]. 
Despite the pharmacological advantages, intradermal injections are not widely 
used.  The standard Mantoux technique requires a specially trained healthcare provider to 
insert a hypodermic needle at a grazing angle above the skin surface into the skin, which 
is approximately 1 – 2 mm thick [145].  Even when performed by trained professionals, 
intradermal localization is unreliable [27].  
 To simplify intradermal delivery, we and others have fabricated hollow 
microneedles that target drug delivery into the skin with needles that are shorter than the 
thickness of the skin [69, 83, 146-154]. These devices are expected to reliably target 
injections into the skin, even by healthcare professionals without special training on their 
use [155]. Additionally, microneedles may improve patient acceptability compared to 
intradermal injections due to their small size and reduced pain [67, 156, 157]. 
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Previous research provides four guidelines to optimize microneedle design.  First, 
microneedles should have a sharp tip to reduce the force required for insertion into the 
skin [69, 158].  Second, microneedles with side-opened lumens, off-center from the tip, 
may reduce injection pressure  by initiating flow away from where the skin is most 
compressed [69, 159, 160].    Third, microneedles need an appropriate combination of 
material strength and geometry to survive insertion into skin without mechanical failure 
[68, 69, 146, 158].  Fourth and finally, the fabrication process should rely only on 
inexpensive methods such as micromolding, ideally rejecting complicated two-piece 
molds or fragile demoldable cores. [150, 153, 161-164]. A microneedle meeting these 
criteria could easily insert into skin, inject at a moderate pressure to reduce patient pain, 
and compete on costs with needles and syringes. 
 In this chapter, we present a fabrication process based on sacrificial micromolding 
and selective electrodeposition meeting the design criteria listed above.  In addition, we 
characterize the device’s insertion into skin and report in vitro and in vivo delivery 
studies  with pig and hairless guinea pig skin. 
3.2 Device Fabrication 
 We fabricated microneedle devices using a seven-step process: (i) fabrication of 
the master structure with a laser-ablated cavity, (ii) creation of a micromold based on the 
master structure (iii) creation of replicas of the master structure using the micromold, (iv) 
sputtering a gold seed layer onto the replicas, (v) selective electrodeposition to form the 
hollow microneedle structure,  followed by (vi) dissolving of the sacrificial replicate 
structure to release the hollow metal microneedle and (vii) integration of the microneedle 
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with a syringe-based pressure source for fluid delivery.  Figure 3.1 shows a schematic of 
the fabrication process, described in detail below. 
 
 
Figure 3.1 Fabrication sequence.  (A) Fabrication of the master structure with a laser 
ablated cavity. (B) Creation of a micromold based on the master structure featuring a 
protruding pillar that will become the lumen exit hole in the final device. (C) Creation of 
a replica using the micromold. (D) Sputtering a gold seed layer onto the replica. (E) 
Electrodeposition of metal everywhere except the cavity, followed by dissolving of the 
sacrificial base material to release the metal microneedle. 
 
3.2.1 Master Structure 
We lathed a brass rod (VS Lathe, Harrison, West Yorkshire, UK) to produce a 
disk measuring 7 mm in diameter and 1 mm in thickness with a tapered cylinder (i.e., 
solid microneedle) measuring 1.1 mm tall, 225 µm in radius at the base, and 20 µm in 
radius at the tip, which was centered on top of the disk. A poly(lactic acid) (PLA) replica 
of the lathed structure was made using PDMS molding and melt casting (Park et al. 
2005).  To accomplish this, the lathed structure was attached to an aluminum dish (5 cm 
diameter, 1.5 cm deep) using double-stick tape, and covered with 15 g of 
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poly(dimethylsiloxane) (PDMS) (Sylgard 184, Dow Corning, Midland, MI).  The PDMS 
was cured at 37°C for 24 h, and the PDMS mold was separated from the lathed structure 
by hand.  PLA pellets (3051D, NatureWorks, Minnetonka, MN) were placed onto the 
PDMS mold, which was then placed in a 195°C vacuum oven.  Vacuum was applied after 
the PLA had melted to degas the polymer and force it into the mold.  After stopping the 
vacuum and cooling the samples, the PLA was separated from the mold by hand.   
After molding, we laser-ablated a cavity in the PLA replica to create the feature 
that forms the lumen exit hole on hollow microneedles.  The 70 µm x 70 µm cavity was 
ablated using a 248-nm excimer laser (Resonetics, Nashua, NH).  The cavity was 
centered ~135 µm below the tip at a 45° angle relative to the base and was ~100 µm 
deep.  The ablated microneedle served as the master structure and template for 
micromolding replicas. 
3.2.2 Replicating the Master Structure 
The PDMS molding and melt-casting procedures described above were used to 
create poly(lactic acid-co-glycolic acid) (PLGA) replicas of the master structure.  The 
PLGA-filled mold was placed in a -20°C freezer for 5 min, taking advantage of 
differences in thermal expansion coefficients of PLGA and PDMS to facilitate 
demolding.  Low molecular weight PLGA (7525 DLG 7A, Surmodics, Birmingham, AL) 
was used because it dissolves rapidly for sacrificial micromolding.  Although the molds 
have a small, non-vertical core (Figure 3.1) that could complicate demolding, we did not 




3.2.3 Seed Layer and Electrodeposition 
We sputtered a gold seed layer onto each PLGA replica using an EMS 500 sputter 
coater (Electron Microscopy Sciences, Hatfield, PA).  To monitor the variance in seed 
layer thickness, we measured the resistance across the diameter of each sample (edge-to-
edge resistance) using a standard Ohmmeter.  Thicker seed layers would have reduced 
edge-to-edge resistance. 
We expect, because of masking effects, much less gold was deposited in the 
cavity compared to the rest of the solid microneedle structure.  Therefore, the resistivity 
inside the cavity would be higher compared to the rest of the sample, enabling selective 
electrodeposition outside the cavity.  As described previously in [165], for a sample with 
heterogeneous resistivity, the reduction of metal from the electroplating bath is more 
difficult on the area of high resistivity compared to the area of low resistivity. 
We electrodeposited nickel onto individual solid microneedle devices using a 
Watts nickel bath (Watts Semi-Bright RTU, Technic Inc., Cranston, RI) and a constant-
current power supply (E3611A, Hewlett Packard, Palo Alto, CA) with a range of 0-850 
mA.   The bath solution was stirred at 700 rpm, and the solution and anode were replaced 
after 36 h of electrodeposition. 
To optimize operating conditions for deposition of metal onto the solid 
microneedle structure, without depositing over the cavity, we varied the seed layer 
thickness (as determined by edge-to-edge resistance) and the starting current of 
electrodeposition (Table 3.1). We tested seed layers with edge-to-edge resistances 
between ~10 Ω  (thick seed layer) to ~44 Ω (thin seed layer).  We varied the starting 
current from 0-9 mA. 
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Table 3.1 Effects of Starting Conditions on Electrodeposition Process Yield 
 
1
 Edge-to-edge electrical resistance (mean ± standard deviation) was used as a proxy 
measure for seed layer thickness. 
2
 Electrodeposition was carried out at a starting current for 6 min at the beginning of the 
process. 
3
 Yield: percent of devices with complete metal deposition on the mold surface and a 
patent lumen exit hole. 
4
 Over-deposition: electrodeposition of metal covering the lumen exit hole. 
5
 Under-deposition: electrodeposition of some metal, insufficient to cover the 
microneedle surface. 
 
Thick seed layers led to immediate over-deposition of metal, filling the cavity and 
preventing hollow microneedle formation.  With thick seed layers, presumably even the 
cavity had sufficiently low resistivity for electrodeposition.  Thin seed layers suffered the 
opposite problem: insufficient metal deposition to cover the microneedle surface.  
For intermediate seed layer thicknesses (R ~ 20 Ω), the deposition pattern 
changed depending on the starting current.  Low currents ( I < 1.65 mA) led to under-
deposition, high currents ( I > 3.0 mA) led to over deposition.  Optimal conditions were 












3 Mode of 
Electrodeposition Failure 
Low 
10 ± 2 
Medium 
1.65 ≤ I ≤ 3.0 
3 0% Immediate over-deposition
4 
Medium 
20 ± 2 
Low 
1.0 ≤ I ≤ 1.65 
3 0% No deposition 
Medium 
22 ± 6 
Medium 
1.65 < I ≤ 3.0 
32 63% Some over-deposition 
Medium 
18 ± 4 
High 
3.0 < I ≤ 9.0 
5 20% Over-deposition 
High 
44 ± 5 
Medium 




deposition and over-deposition suggests selective electrodeposition is driven by seed 
layer resistivity differences in the cavity.  
After 6 min at the starting current, we expedited the electrodeposition process by 
ramping up the current by 0.125 mA/min to a peak current of 4.75 mA for 2 h.  Although 
the current increased, we did not lose the selectivity of the electrodeposition.  We believe 
this was because as metal was deposited outside the cavity, the resistivity of the 
microneedle surface decreased and thereby increased the selectivity of metal deposition 
outside the cavity. 
3.2.4 Dissolving the Sacrificial Replicate Structure 
After this electrodeposition process, samples were inspected using bright-field 
microscopy (SZX 16, Olympus, Center Valley, PA).  By shining a light on the backside 
of the sample, we determined which samples had maintained a patent lumen exit hole by 
seeing if the light passed through (Figure 3.2B).  Samples passing inspection were 
suspended in an acetone bath stirred at 100 rpm for 1 h.  The PLGA and the seed layer 
inside the cavity dissolved and disintegrated, releasing the metal hollow microneedle.  
We then electrodeposited a second time on these samples at 5.5 mA for 2 h to increase 
the metal thickness with no risk of over-deposition.  The final metal thickness of five 
representative samples was 12.4 ± 1.4 µm, measured using brightfield microscopy. 
3.2.5 Device Assembly 
 The fabricated microneedle was glued (Epoxy Plastic Bonder, Loctite, Rocky 
Hill, CT) to an acrylic device holder with a half-cylinder shape and aligned with a 3 mm 
diameter through-hole. The flat edge of the acrylic was glued using cyanoacrylate glue 
(Super Glue Gel, Loctite, Rocky Hill, CT) onto a nylon female luer lock cap (McMaster-
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Carr, Atlanta, GA) which also had an aligned 3 mm diameter through-hole.  The finished 
assembly was mounted onto a syringe. 
3.2.6 Final Device Imaging 
Images of fabricated hollow microneedles are shown in Figure 3.2. Figure 3.2A 
shows a hollow microneedle after the fabrication process.  Figure 3.2B shows light 
passing through the lumen exit hole.  Metal can also be seen inside the needle in Figure 
3.2B.  This short, tubular vestige from the cavity reveals the boundary of selective 
electrodeposition. .  Figure 3.2C shows a PDMS mold used for the micromolding-based 
fabrication.  Figure 3.2D is an image of a microneedle assembled onto a luer hub for 
connection to a syringe. 
.  
Figure 3.2 Optical microscopy images of the microneedle device. (A) Hollow 
microneedle imaged with direct lighting. (B) Hollow microneedle imaged with light 
shining through the backside, which illuminates the lumen exit hole of the microneedle. 
(C) Cross-section of the PDMS micromold with arrow pointing to demoldable core that 
forms the lumen exit hole of the microneedle. (D) Device assembly used for injections 
with a hollow microneedle glued to a curved acrylic surface mounted on a luer lock. 
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3.3 Force Displacement Measurement 
We followed a method described previously [166] to characterize the axial failure 
force of the microneedles.  Briefly, the needles were pressed against a steel plate at a 
constant speed until a discontinuity was observed in the force versus displacement graph.  
The force at the onset of the discontinuity was the measured failure force.  
3.3.1 Experimental Results 
The axial failure force for the hollow microneedles was 0.74 ± 0.11 N (average ± 
standard deviation, n =5 replicate measurements).  A representative force-displacement 
curve is shown in Figure 3.3.  Visual observation showed the mode of failure was 
telescopic collapse of the needles similar to seen previously with hollow metal 
microneedle [158].  The predicted force required to insert a needle with this tip geometry 
into human skin is 0.086 N [158].  The measured failure force is close to an order of 




Figure 3.3 Representative force-displacement curve for a microneedle pressed against a 
rigid surface.  A discontinuity representing microneedle failure is seen at 0.025 mm 
displacement with a peak force of 0.072 N. 
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3.4 Insertion and Injection into Pig Skin In Vitro 
3.4.1 Insertion into Pig Skin 
To validate the prediction that our microneedles should be able to be inserted into 
skin without mechanical failure, we pressed  microneedles into pig skin in vitro, and then 
stained the insertion sites with gentian violet (Humco, Texarkana, TX), which selectively 
stains sites of microneedle penetration and not intact skin [156]. The microneedles were 
mounted onto a 3 ml syringe and applied to the skin by hand. As shown in Figure 3.4A, 
gentian violet staining confirmed the hollow microneedles were able to penetrate skin.  
We made four microneedle insertion attempts in this way each using a different 
microneedle, and all of them provided effective skin penetration. Additional successful 
microneedle insertions accompanied by fluid injection are described below.  
 
 
Figure 3.4 Microneedle injection into pig skin in vitro. (A) Photograph of skin surface 
after insertion of four microneedles followed by gentian violet staining (arrows indicate 
insertion sites). The stain demonstrates penetration of the microneedles into skin. (B) 
Fluorescence microscopy image of a skin cross-section after injection of red-fluorescent 
sulforhodamine B using a microneedle. (C) Magnified view showing the site of needle 
insertion into skin. 
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3.4.2 Injection into Pig Skin 
We also verified the microneedles could inject fluid into skin.  Using 
microneedles mounted onto 3 ml syringes, we applied thumb pressure for 20 s to inject 
0.1 ml of a 1 mM solution of a fluorescent dye, sulforhodamine B (Sigma-Aldrich, St. 
Louis, MO), in phosphate-buffered saline (PBS) (Sigma-Aldrich).  After injection, 1 cm x 
1 cm pieces of skin were cut out, sectioned, embedded in Optimal Cutting Temperature 
compound (Sakura Finetek, Torrance, CA), and frozen on dry ice. The skin was cut into 
10 µm sections using a Microm cryostat (Thermo Fisher, Walldorf, Germany).  Skin 
sections, excited by a BH2-RFL-T3 light source (Olympus, Center Valley, PA), were 
photographed using a SZX16 microscope and DP71 camera (Olympus) to examine the 
distribution of sulforhodamine B in the skin. 
Figure 3.4B shows a representative histological cross-section of the 
sulfrohodamine B delivery confirming these microneedles can deliver fluid into skin.  
The needle insertion site is shown at greater magnification in Figure 3.4C. We examined 
three skin sites after injection in this way, each using a different microneedle, which 
resulted in intradermal injection. 
3.5 Insertion and Injection into Hairless Guinea Pig Skin In Vivo 
We tested insertion and injection using microneedles in vivo on a hairless guinea 
pig (Charles River Laboratory, Wilmington, MA) with approval from the Georgia Tech 
Institutional Animal Care and Use Committee (IACUC).  The guinea pig was 
anesthetized using isofluorane gas in oxygen and sustained in anesthesia using a nose 
cone.  The microneedle was manually inserted into the skin on the back of the guinea pig, 
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and pressure was applied to the syringe plunger by hand.  We delivered approximately 50 
– 75 µL of a 1 mM solution of sulforhodamine B in PBS.  We measured the peak 
pressure using a digital manometer (Model 220-95, Netech, Farmingdale, NY). After 
delivery, we applied gauze to the delivery site for 10 s and then placed the gauze in 4 mL 
of PBS for 30 min.  The PBS solution was analyzed using a fluorometer (Spectramax 
Gemini XS, Molecular Devices, Sunnyvale, CA) to determine the amount of dye leaked 
onto the skin surface.  At the end of the experiment, the guinea pig was euthanized using 
carbon dioxide and 1 cm x 1 cm pieces of skin and subcutaneous tissue were cut into 14 
µm-thick sections as frozen sections and imaged as described above.  Images were split 
into red, green, and blue channels using Image J.  The fraction of dye delivered to the 
skin was calculated as the red intensity in the epidermis and dermis divided by the red 
intensity of the whole tissue section. 
3.5.1 Experimental Results 
Figure 3.5 shows a representative photographic image and histological cross-
section of an injection site after microneedle injection into a guinea pig.  The peak 
pressure for intradermal injection with microneedles was 16.4 ± 2.6 psig (average ± 
standard deviation, n = 3).  Using the image analysis technique described above, the 
mean fraction of dye delivered to the skin is 90 ± 7%(n = 4; two from guinea pig, two 




Figure 3.5 Microneedle injection into hairless guinea pig skin in vivo. (A) Photograph of 
the skin surface on the back of the animal showing injection of red-colored 
sulforhodamine B into the skin. (B) Fluorescence microscopy image of a skin cross-
section after injection of red-fluorescent sulforhodamine B using a microneedle. On 
average, 90% of the dye was localized in the skin, which demonstrates effective targeting 
to the skin.   
 
3.6 Discussion 
We fabricated and tested hollow microneedles with the following advantageous 
features: (i) sharp tips, (ii) lumen exit holes located on the side of needles just below the 
tips, (iii) metal as the material of construction, and (iv) a micromolding-based fabrication 
process.   
Human skin thickness varies across the body, but is generally 1 – 2 mm thick 
[167].  Here, we used microneedles measuring 1.1 mm in length to target injection into 
the skin by pressing the needle perpendicularly against the skin surface. This method 
should improve upon the conventional Mantoux technique that is unreliable even for 
trained experts.  
The choice of fabricating a single, conical microneedle with a 20-25° taper was 
based on the observation that similarly shaped glass microneedles fabricated by pulled-
glass micropipette techniques could insert into skin and deliver up to 1 mL of fluid in 
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human subjects [67].  The needles we fabricated were similarly able to insert into skin 
and inject fluid without leaks.  The ratio of microneedle failure force to predicted skin 
insertion force of approximately 9 provides a large safety margin, allowing reliable 
insertion without fracture. This large safety margin was enabled by reducing insertion 
force by having a sharp needle tip and increasing needle strength by using metal as the 
material of construction.  
Micromolding of hollow microneedles is challenging. For this reason, most 
previous studies have used direct fabrication methods: high precision etching, grinding, 
or laser ablation in the production stage. [54, 69, 146, 149, 168]. These methods are less 
attractive for inexpensive mass production because they require the use of sophisticated 
fabrication equipment often in a high-cost cleanroom environment to make each device. 
Direct fabrication of master structures followed by indirect molding-based replication 
should be much less expensive and enable the large-scale mass production needed for 
disposable needles. Among molding methods in the published literature, most have 
lumen exits at the microneedle tip which reduces sharpness and may impede fluid flow 
into tissue [83, 150, 154, 169].  Others have made molded hollow microneedles with 
side-opening lumen exit holes, but the molds were complex: either two-piece, aligned 
molds [163] or molds with seemingly fragile demoldable cores [147]. 
We introduced a fabrication method that lends itself to simpler mass production 
and produces microneedles with a sharp tip and side-opening lumen exit hole. After laser 
fabrication of a master structure, the master structure was repeatedly used to produce 
female micromolds. These micromolds were in turn used to make replicate structures 
employed as male micromolds for electrodeposition to produce metal microneedles. 
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While this approach involves an additional step to make the male micromolds compared 
to prior methods, it is an improvement because (i) it uses high-throughput molding 
methods to produce the microneedle devices and employs the lower-throughput laser 
etching process only to make the re-usable master structures and (ii) is able to mold metal 
microneedles with improved geometry that enable insertion and injection into skin.  
The lumen exit hole was created by using a laser-generated divot in the master 
structure, which appeared to inhibit seed layer deposition and later electrodepositon. The 
divot in the master structure became a protruding core in the intermediate replicate mold, 
which might be expected to introduce complications in molding, especially during 
demolding. However, PDMS as the mold material provided sufficient flexibility and 
allowed reliable demolding with damaging the mold or the demolded structure.  
We needed a balance to deposit metal onto the surface of the male mold, but not 
deposit metal within the cavity forming the lumen exit hole. A thin seed layer or a high 
starting current both led to over-deposition that covered the cavity. A medium seed layer 
thickness and a moderate starting current minimized over-deposition and enabled 
fabrication of suitable structures with reasonable yields. Further optimization of the 
microneedle geometry and electrodeposition process could improve yield. 
Overall, this fabrication process produces metal hollow microneedles with simple, 
one-piece molds. Using an excimer laser to define the master geometry allowed precise 
positioning of the microneedle hole, and the PDMS-based molds were reproducible and 
reusable even with the angled pillar.  The selective electrodeposition process may have 
other uses in microfabrication.  Potential uses include depositing metal up to a certain 
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distance/elevation, avoiding deposition in high-aspect-ratio holes, or bonding two 




INSULIN DELIVERY USING MICRONEEDLES TO TYPE 1 
DIABETIC CHILDREN AND ADOLESCENTS 
 
4.1 Introduction 
For children, adolescents, and adults with Type 1 diabetes, the most important 
goals are to improve compliance with diabetes management and prevent the long-term 
complications due to hyperglycemia. To address these needs, we evaluated the use of a 
single, hollow microneedle, less than 1 mm in length, to administer rapid-acting Lispro 
insulin to children and adolescents with Type 1 diabetes. We expect patient compliance 
to improve due to the microscopic length of the microneedle because of a reduction in 
pain and apprehension as compared to subcutaneous administration. We also expect the 
faster onset and offset of insulin pharmacokinetics due insulin delivery to the skin should 
improve closed-loop insulin therapy by being more responsive to changes in blood 
glucose levels.  
Omission of insulin injections due to fear of needles is common in children and 
adolescents [3, 28, 170, 171]. Twenty-five percent of children and adolescents admit to 
omitting or underdosing injections due to needle phobia or anxiety [172, 173].  Fear and 
omission of injections correlate with worse HbA1C levels for children [1-3], leading to 
more frequent hospitalization and higher cost [174-176].   
Improved needle designs may improve compliance with insulin therapy.  Pen 
devices, shorter needles, and injection ports have provided small compliance 
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improvements in adults and children [177-179].  Small reductions in needle size have 
been helpful, however, microneedles are up to an order of magnitude shorter, and may be 
even more effective at reducing pain and apprehension.  Typical fine needles for 
subcutaneous injection are 4-8 mm in length and 0.2-0.3 mm in diameter.  In contrast, 
microneedles are typically less than 1 mm in length and 0.1 mm in diameter [8, 180].  In 
blinded trials, microneedles are less painful than hypodermic needle injections, and the 
reduction in pain is proportional to the reduction in needle length [156, 181].  In addition 
to patient reports of microneedles being less painful than subcutaneous injections, 
physicians have also agreed that microneedles would be less painful and provide a 
beneficial option for patients on insulin therapy [157].  These findings suggest that 
microneedles can improve compliance in children and adults because of reduced needle 
pain and apprehension. 
Microneedles may also enable closed-loop therapy by reducing the lag time for onset and 
offset of insulin action.  Closed-loop therapy is currently limited largely by long lag times 
associated with insulin delivery and glucose measurements, necessitating advanced 
algorithms to make accurate predictions of required insulin doses [88, 182]. These lag 
times do not exist in the normal pancreas, which is how a properly functioning pancreas 
can maintain tight control over blood glucose levels. Microneedles may enable closed-
loop therapy by reducing the lag time for insulin onset and offset, thereby allowing 
closed-loop therapy to more rapidly respond to changes in blood glucose levels and ease 
the requirement to predict insulin delivery needs. Studies in adults have shown that 
intradermal infusion of insulin using microneedles leads to much faster uptake and 
subsequent clearance of insulin lispro and regular human insulin compared to 
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subcutaneous delivery. This is thought to be due to the enhanced venous and lymphatic 
access in the skin compared to the subcutaneous space [10, 11, 41, 42, 44]. 
Thus, microneedles offer two major routes to improved management of Type 1 
diabetes: (i) improving compliance, especially in children and adolescents with needle 
phobia and anxiety, and (ii) accelerating insulin pharmacokinetics to enable more 
responsive closed-loop therapy.  Although data on intradermal insulin delivery exist for 
adults [10, 183], it is unknown if microneedles reduce pain in children and adolescents 
for insulin administration or any other application.  It is also unknown if rapid uptake of 
insulin after intradermal injection will occur in children and adolescents.  We believe this 
is the first study of microneedles in a pediatric population for any application (although 
two pediatric participants were included as part of a larger population studied by our team 
[10]).   
We conducted this trial in a pediatric population to test the hypotheses that 
delivery of lispro insulin using a microneedle results in (i) less needle-insertion and 
infusion pain and (ii) faster pharmacokinetics compared to traditional subcutaneous 
insulin delivery.  
4.2 Research Design and Methods 
Sixteen participants were recruited from patients followed in the Diabetes clinic at 
the Emory Children’s Center Division of Pediatric Endocrinology.  Subjects were 10-18 
years of age, had Type 1 diabetes for at least 2 years, were using a conventional insulin 
pump for at least the past year, and had a BMI below the 85
th
 percentile (see Table 4.1). 
Subjects were excluded if they had type 2 diabetes, acanthosis nigricans, a major organ 
disease, an insulin requirement > 150 U per day, or a cognitive impairment (more than 
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two grades behind age-appropriate grade).  Female subjects were excluded if they were 
pregnant or nursing. On the day of the study, all subjects were healthy, afebrile, and had a 
blood glucose level between 100 and 200 mg/dL. 
This repeated-measures study involved microneedle and subcutaneous 
administration of insulin on separate days.  The order of procedures was randomized 
using spreadsheet software.  No investigators were aware of the order until the day of the 
study.  Eight out of sixteen patients had microneedle administration first.  No changes 
were made to the study design during the course of the study.  This study was approved 
by the Emory University Institutional Review Board. 
Study visits took place in examination rooms at the Emory Children’s Center 
(Atlanta, GA).  Subjects fasted the night before the study starting at 10 PM, arrived at the 
study site at 7 AM, and had an intravenous catheter inserted in the antecubital fossa.  
After intravenous catheter placement, a 10 mL initial blood specimen was collected, after 
which, insulin Lispro (U50) was administered by either the microneedle or subcutaneous 
route using a syringe pump set at a flow rate of 1.0 mL/min.  The insulin dose was based 
on the subject’s insulin-to-carbohydrate ratio for a 75-gram carbohydrate meal.  Insulin 
dosing ranged from 10 – 20 U (i.e., 200 – 400 microliters of a U50 insulin Lispro 




Figure 4.1 Microneedle used for intradermal insulin delivery. (A) Magnified view of a 
microneedle (see arrow) mounted on a curved holder. Scale bar is 1 mm. (B) Magnified 
view of a hypodermic needle used to insert a subcutaneous insulin catheter. Scale bar is 1 
mm. (C) Device to hold and insert microneedles into skin. Arrow shows location where 
microneedle protrudes from the device. (D) Characteristic intradermal bleb (see arrow) 
on the abdomen of a participant after microneedle delivery. 
 
For microneedle administration, the microneedle holder was placed on the skin, 
after which the microneedle was inserted into the skin to a microneedle length of 1.1 mm 
and then retracted to a final microneedle length of 0.9 mm prior to infusion.  Figure 1A 
and Figure 1B compare a microneedle and a subcutaneous needle and catheter at the 
same magnification.  Microneedles were made at Cartika Medical (Maple Grove, MN) 
and mounted in a microneedle holder (Figure 1C) described previously [41]. An 
investigator placed the microneedle in the microneedle holder and inserted the 
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microneedle into the skin in a rotating, drilling manner to minimize skin deflection during 
microneedle insertion, as described previously [10]. After infusion, the microneedle was 
retracted slowly (15 s) and a characteristic intradermal bleb was observed (Figure 1D).  
For subcutaneous administration, a 9-mm MiniMed infusion set (Medtronic, 
Minneapolis, MN) was used and inserted with the manufacturer’s spring-loaded inserter 
by an investigator.  All insulin delivery injections were performed on the subject’s 
abdomen. 
After insulin administration, subjects immediately ate a standard 75-gram carbohydrate 
meal. The meal was identical for all subjects on both study days.  Blood was collected 
from the intravenous catheter every 15 min for 2 h and then every 30 min for an 
additional 2 h.  Data collection was stopped if subjects developed hypoglycemia (blood 
glucose < 60 mg/dl) or symptomatic hyperglycemia as measured by a hand-held 
glucometer. Blood was collected in EDTA-containing tubes and then centrifuged, 
separated, and frozen immediately after collection.  The frozen plasma specimens were 
assayed at the Emory Children’s Center for glucose concentration (Glucose Colometric 
Assay Kit, Cayman Chemical, Ann Arbor, MI) and free Lispro insulin concentration 
(LisPro Insulin RIA, Millipore, Billerica, MA).  
Outcome measures included pain measurements, plasma insulin concentration vs. 
time, and plasma glucose concentration vs. time.  Pain was measured after insulin 
administration using a 100-mm slider as a visual analog scale (VAS).  An investigator 
blinded to the administration method measured subjects’ insertion and infusion pain. 
All statistical analyses compared microneedle and subcutaneous administration 
within subjects.  Sample size was determined based on the number of subjects needed to 
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achieve statistically significant differences in the area under the insulin curve (AUC), 
pain, and time to peak insulin concentration (tmax). Thirteen subjects were needed to 
detect a difference of 15 min with a standard deviation of 15 in tmax at a power of 90% 
and an alpha of 0.05. Only seven subjects were needed to detect a difference of 15 mm 
with a standard deviation of 10 in pain with insertion at a power of 90% and an alpha of 
0.05. Therefore, given the possibility of up to a 20% dropout or loss-to-follow-up rate, we 
enrolled sixteen subjects.  
Insertion and infusion pain were compared with paired t-tests.  A pharmacokinetic 
model with first-order insulin absorption and elimination was fit to all participants’ 
insulin curves [42].  tmax, offset time (time to return to half the peak concentration, t1/2), 
AUC were derived from the pharmacokinetic fit.  Time values were compared using 
paired t-tests.  AUC and the pharmacokinetic coefficients from the model were compared 
using ratio paired t-tests.  One post-hoc test examined the significance of the correlation 
between microneedle dose and tmax.  
4.3 Results and Discussion 
 Sixteen subjects enrolled in this study and were seen between February 2009 and 
January 2012.  Four participants’ data sets were excluded from the analysis.  One subject 
had an elevated insulin level at time 0 that was likely due to a bolus infusion for mild 
hyperglycemia that the subject did not inform the investigators of.  Three others received 
incomplete doses of insulin due to a mechanical issue with the microneedle holder. Three 
subjects developed hypoglycemia at 3 h after both methods of insulin administration.  No 
other clinically significant events occurred.  The final analysis includes 12 subjects for 3 
h.  Participant demographics are shown in Table 4.1. 
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Table 4.1. Participant Demographics 
 
Sample size Number enrolled n = 16 
 Number included in analysis n = 12 
Gender Male n = 6 (50%) 
 Female n = 6 (50%) 
Age 11 – 12 n = 3 (25%) 
 13 – 14 n = 1 (8%) 
 15 – 16 n = 6 (50%) 
 17 – 18 n = 2 (17%) 
Race / Ethnicity Caucasian / White n = 8 (67%) 
 African American / Black n = 4 (33%) 
HbA1C average 7.0 – 7.4 % n = 6 (50%) 
 7.5 – 7.9% n = 4 (33%) 
 8.0 – 8.4% n = 2 (17%) 
BMI 17 – 19 n = 3 (25%) 
 20 – 24 n = 6 (50%) 





Initially, pain was assessed by evaluating the VAS score after insertion of 
microneedles and subcutaneous catheters and by infusion of insulin solution. 
Microneedle insertion was significantly less painful than subcutaneous catheter insertion 
(Figure 2, ∆VAS = -9.9,  p = 0.005). Ten of the twelve subjects rated microneedle 
insertion as less painful than catheter insertion. Pain was also assessed after insulin 
infusion. There was no significant difference between pain experienced by subjects after 
infusion of insulin using the microneedle or subcutaneous catheter delivery (Figure 2, 
∆VAS = 13.2, p > 0.05).  
 
 
Figure 4.2 Pain of microneedle and subcutaneous insulin administration. Participants 
scored pain associated with insertion into skin and associated with insulin solution 
infusion using microneedles and subcutaneous catheters. The data represent average 
values from 12 participants. Error bars represent the standard error of the mean.  




Microneedle administration resulted in a faster onset and offset of insulin action 
(Figure 3A).  The average time to peak insulin concentration (onset time) was 30 ± 2 min 
after microneedle administration and 52 ± 4 min after subcutaneous infusion (Figure 4A).  
The onset time for microneedle delivery was 22 min faster, a reduction of more than 40% 
(p = 0.0004).  The offset time was also significantly faster for microneedle administration 





Figure 4.3 Pharmacokinetics and pharmacodynamics of insulin delivery. (A) Average 
insulin concentration vs. time. (B) Plasma glucose concentration vs. time. Black circles = 
microneedle, black squares = subcutaneous. The data points represent average values 
from 12 participants. Error bars represent the standard error of the mean. The lines 
represent the average of the fits from the pharmacokinetic model: solid line = 





Figure 4.4 Pharmacokinetic analysis of intradermal insulin delivery using microneedles. 
(A) Insulin onset time for microneedle (black bars) and subcutaneous (white bars) 
administration. (B) Parameters derived from the pharmacokinetic model after delivery of 
insulin using microneedles and subcutaneous infusion: insulin absorption coefficient (ka) 
insulin elimination coefficient (ke) and area under the insulin curve normalized by dose 
delivered (AUC/dose). The data represent average values from 12 participants. Error bars 
represent the standard error of the mean. * = significant at p < 0.05.  ** =  significant at  
p = 0.0002. 
 
Pharmacokinetic modeling provides additional measures for comparison between 
the two delivery methods. The absorption coefficient was 3.7 times higher for 
microneedle administration (Figure 4B), consistent with the faster onset and offset times.  
The elimination coefficients were not significantly different (Figure 4B), indicating that 
once insulin reaches the bloodstream by either route, it is eliminated at the same rate. 
Finally, the AUC values were statistically indistinguishable between the two groups 
(Figure 4B). This is expected because the same amount of insulin was delivered by each 
route to each subject.   
The pharmacodynamic response to insulin delivery after ingestion of a standard 
carbohydrate meal is shown in Figure 3B. After insulin administration by either route, 
plasma glucose level rose over the course of 30 min, which is expected after consuming 
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food.  After microneedle delivery, glucose levels plateaued for the remainder of the 
study, whereas glucose levels decreased and returned to baseline in subjects receiving 
subcutaneous insulin.  
This study tested the hypothesis that insulin delivery using microneedles causes 
less insertion and infusion pain in children with type-1 diabetes compared to conventional 
subcutaneous injection. Consistent with this hypothesis, we found that children rated 
insertion of microneedles as significantly less painful than introduction of a subcutaneous 
catheter.  This is consistent with earlier studies of microneedles in adults [10, 156, 181] 
suggesting that microneedles may be useful for increasing insulin therapy compliance 
among children as well.  This first study of microneedles in children also suggests use of 
microneedles for therapy in other pediatric indications for improved compliance.   
Insulin delivery using microneedles did not cause less infusion pain compared to the 
subcutaneous route.  This is also consistent with earlier results [10, 42].  Some strategies 
to reduce infusion pain associated with microneedles include: lowering the flow rate, 
adding a spreading enzyme such as hyaluronidase, and increasing the size of the needle 
lumen to reduce the hydrostatic pressure [67].  Adopting these strategies may also reduce 
the likelihood of incomplete delivery with microneedles, which possibly occurred in our 
studies.   
This study also tested the hypothesis that intradermal insulin delivery using 
microneedles leads to faster onset and offset of insulin pharmacokinetics compared to 
subcutaneous injection. Consistent with this hypothesis, we found that insulin 
administered with microneedles had significantly faster onset and offset of insulin action.  
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Both the onset and offset times were reduced.  This is consistent with previous 
pharmacokinetic studies of microneedles in adults [10, 11].  
We believe that the reason for accelerated pharmacokinetics after insulin 
administration using microneedles involves targeting insulin delivery to the skin, which is 
enabled by the small size of microneedles. Skin delivery may target the rich capillary bed 
found in the superficial dermis, explaining the rapid insulin onset. An alternate 
explanation is that insulin injection into skin leads to rapid insulin uptake via lymphatic 
drainage [44, 184]. This study does not provide further insight into mechanism but does 
demonstrate accelerated pharmacokinetics with intradermal delivery.  
In this study, post-prandial glucose for the microneedle group initially increased by 
approximately 30 mg/dl and then plateaued.  A similar pharmacodynamic profile 
occurred in a study of adults all receiving an insulin dose at 0.125 U/kg [42] and in the 
30% -under-dosed arm of a multi-arm study where participants received individualized 
doses [183].  The optimally-dosed arm in the latter study, in contrast, had a small but 
significant improvement in post-prandial glucose levels for intradermal insulin delivery.  
This suggests that optimizing dose for intradermal delivery is important to controlling 
post-prandial glucose levels, and that participants in our study may have been under-
dosed overall.  Microneedle administration to the skin, with faster onset and reduced 
persistence of insulin, may be better suited to rapidly responsive, closed-loop insulin 
therapy rather than standard subcutaneous insulin injections.  The fast onset and fast 
offset could reduce problems with closed-loop insulin delivery caused by slow insulin 
response and persistence of insulin in the blood, such as the rapid rise of post-prandial 
glucose and the glucose peak above acceptable ranges caused by slow onset of insulin 
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action and the hypoglycemia caused by slow offset of insulin [88, 182].  Compared to 
implants being studied for closed-loop therapy that deliver intraperitoneal insulin with 
rapid pharmacokinetics [4], microneedles may offer a minimally invasive and more 
widely acceptable approach. 
To improve closed-loop control, further reductions in onset and offset time with 
microneedles could be explored.  For example, additional statistical analysis of our data 
showed that the time to peak insulin concentration was significantly shorter in subjects 
receiving smaller insulin doses delivered with the microneedle (p < 0.02).  A similar 
correlation was previously observed and modeled for subcutaneous insulin delivery too 
[185]. Given this observation, it is possible that switching from a single injection on the 
order of 100 µl (as done in this study) to multiple injections on the order of, for example, 
10 µl (using, for example, an array of multiple microneedles) could accelerate the uptake 
of intradermal insulin.  Other strategies exist for accelerating the pharmacokinetics of 
insulin uptake including injecting hyaluronidase [186], warming the injection site [187], 
and creating a more soluble insulin formulation [87].  Combining these methods with 
microneedles may produce a synergistic effect resulting in ultra-fast insulin uptake.   
Limitations of our study include small sample size with limited demographic distribution 
and examination of only single insulin injections. To generalize our results toward 
possible future clinical adoption, additional studies are needed with larger pediatric trials 
and application of multiple insulin doses over multiple days to better assess dose-to-dose 
reproducibility of pharmacokinetics and pharmacodynamics, as well as long-term safety, 
tolerability, compliance and glycemic control. While the microneedles used in this study 
were made of borosilicate glass, we have also made similar microneedles out of medical-
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grade stainless steel [188] and believe these metal microneedles will be more suitable for 




USABILITY, ACCEPTABILITY, AND COST-EFFECTIVENESS OF 




Vaccines save lives, but vaccine administration needs improvement to increase 
coverage and reduce costs [189]. This is especially true for influenza vaccination, where 
coverage rates are well below recommended levels and vaccination costs exceed $2 
billion per year [5, 7, 190]. Self-administered vaccines, made possible by recent advances 
in vaccine delivery technology such as microneedle patches, are expected to improve 
coverage and cost-effectiveness [47]. This study, using microneedle patches to simulate 
influenza vaccination, provides the first measurements of the impact of self-vaccination 
on coverage and cost-effectiveness. 
The United States (US) recommends universal seasonal influenza vaccination but 
achieves just 45% coverage [5], leaving influenza as the 8
th
 leading cause of death [191] 
with over 200,000 hospitalizations [6] and 3,000-49,000 deaths [192] each year. 
Coverage levels for other voluntary vaccines are as low as 14% [193]. These low 
coverage levels are caused in part by fear of needles and inconvenience for patients. 
Needle phobia causes at least 7-8% of vaccination non-compliance [194] , and 
inconvenience ranks as high as second as a reason for skipping influenza vaccination 
[195-197]. 
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Although increased vaccination coverage reduces morbidity and mortality, it 
further increases vaccination costs. Thus, reduced vaccination cost is of great interest. 
The key barriers to improving cost-effectiveness of influenza vaccination are 
administration costs and patient time, which outweigh the cost of the vaccine itself 3.3 to 
1 [7].  
To improve coverage and cost-effectiveness, new vaccination methods need to 
overcome needle-phobia, inconvenience, and high costs of vaccine administration. We 
propose to achieve this improvement using microneedle patches for high-throughput 
vaccination by healthcare personnel or self-vaccination by patients themselves. 
Microneedles patches contain arrays of needles measuring hundreds of microns in length 
that target vaccine delivery to the skin in a simple, minimally invasive and painless way 
[8, 74]. Microneedles can be manufactured at low cost by leveraging tools of the 
microelectronics industry as solid needles made of metal or polymer that encapsulate or 
are coated with vaccine that is released by dissolution in the skin within minutes.  
Other approaches proposed for simplified or self-vaccination include intranasal, 
sublingual, oral, inhaled, edible and transcutaneous vaccines [198]. Only one vaccine, 
oral typhoid, has been approved for self-administration, with an estimated 3 million 
vaccine series administered per year worldwide [12, 199]. Microneedle patches, however, 
are especially attractive because they are compatible with live, inactivated and subunit 
vaccines [200, 201], administer a consistent dose [66, 202], offer the possibility of 
thermostability [79, 203] and can be manufactured inexpensively [8]. Additionally, 
microneedle-based influenza vaccines are expected to be well accepted by practitioners 
and the general public [57, 204, 205] and, as an intradermal delivery method, are more 
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immunogenic, as shown by non-inferiority at 20-60% of the full dose [54, 206] and 
superior seroprotection for older adults at full dose [207]. Microneedle patches have been 
used previously for self-administration of parathyroid hormone, but usability was not 
specifically studied [43]. A hollow microneedle device for self-injection of influenza 
vaccines was usable, safe, and effective [208].  In that study, in which the majority of 
participants worked in a healthcare setting, those who experienced self-vaccination were 
more likely to accept it in the future. 
Despite interest in self-administration of influenza vaccines, there are no 
published data on self-administration of microneedle patches or on the effect of self-
vaccination on vaccination coverage and cost-effectiveness. We therefore conducted a 
study on the usability, acceptability, and cost-effectiveness of microneedle patches for 
influenza vaccination to test three central hypotheses. First, participants can correctly 
apply microneedle patches with minimal training. Second, intent to vaccinate increases if 
a self-administered microneedle patch is offered to participants. Third, self-vaccination 
against influenza results in less cost to improve coverage compared to traditional 
vaccination. 
Three minor objectives were included to compare the pain of microneedle patch 
administration and intramuscular (IM) injection, evaluate a hypothetical high-
effectiveness patch for acceptability and cost-effectiveness, and weigh the factors 




5.2.1 Microneedle Patch Fabrication 
 We bent etched, stainless steel microneedles 90° out-of-plane, cut adhesive foam 
backing and liner material (TM9942, MacTac, Stow, OH) with an arbor press, and cut 
polyacetal packing pieces with a CO2 laser. Parts were assembled with double sided 
adhesive (1522, 3M, Minneapolis, MN) and sent for ethylene oxide cycles. These placebo 
microneedles were designed to mimic coated microneedles [209]. 
5.2.2 Study Approval and Participant Recruiting 
 This study was approved by the Georgia Institute of Technology Institute Review 
Board, and informed consent was obtained from all participants.  We used a venue 
sampling method [210, 211] to obtain a high response rate.  Eligible participants were 
healthy, non-pregnant adults with no diseased skin, no pain perception problems, and no 
allergies to compounds used in the study.  Seventy participants were recruited from 
Atlanta, GA between 9/11 and 5/12.  Participant demographics are in Table 5.1.  Because 
males and participants with a household income less than $20,000 were overrepresented, 
we modified our venue list during the study.  Participants ranged from 18-62 years old, 
and all participants were naïve concerning microneedle use. 
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Table 5.1 Participant Demographics 
 
Trait Value Count Percentage of Sample 
(n=70) 
Gender 
Male 43 61% 
Female 27 39% 
Race/Ethnicity 
White 30 43% 
African American / Black 32 46% 
Other 8 11% 
Education 
High school or less 28 40% 
Associates degree 10 14% 
College degree or more 32 46% 
Age 
18-19 4 6% 
20-29 25 36% 
30-39 13 19% 
40-49 16 23% 
50-59 11 16% 
60+ 1 1% 
Income 
Less than $20,000 18 26% 
$20,000 - $40,000 17 24% 
More than $40,000 26 37% 




5.2.3 Experimental Procedures 
 Participants experienced three un-blinded procedures in a random order: self-
administration of three microneedle patches, investigator-administration of a microneedle 
patch, and investigator administration of 0.5 mL IM saline injection.  Patches were 
applied with thumb pressure.  A computer application set the random order, with 46% of 
participants (32/70) experiencing self-administration before investigator-administration.  
Participants had written instructions for self-administration, and were told to push harder 
if their administration attempts failed.  Pain ratings were collected using a visual analog 
scale (VAS).  All participant input was collected using a computer to minimize reactivity. 
5.2.4 Skin Staining to Measure Usability 
 After each patch application, we applied a dye to evaluate usability. We 
hypothesized more than 85% of people could correctly administer a microneedle patch, 
defined as >85% of needles observed as inserted. Expecting 67 of 70 participants to 
administer the patch correctly, we had 83% power for this hypothesis. Gentian violet and 
fluorescein were applied to different skin tones at investigator’s discretion and imaged 
using a standard camera. Gentian violet 1% (Humco, Texarkana, TX) was pooled for 1 
min, dabbed with gauze, and cleaned with alcohol after 5 min. Fluorescein 10% (Akorn, 
Lake Forest, IL) was diluted to 1% in saline, applied lightly with a cotton swab, dabbed 
with gauze, and cleaned with alcohol after 5 s. Fluorescein stains were imaged under blue 
LED light with blue glass as an excitation filter and a photography filter for emission 
(5558, Tiffen, Hauppauge, NY). Usability was quantified by counting insertion sites, 
uniformly and linearly narrowing the color balance on some images. Uncertain points, 
such as those covered by blood, were excluded from counts. 
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5.2.5 Questionnaires to Measure Acceptability 
 An adaptive survey solicited participants’ willingness-to-pay for vaccination 
options. Participants chose between an IM injection, no vaccination at all, or a 
microneedle patch option. The IM injection had a fixed price (the lower of $25 or the 
participant’s current out-of-pocket cost). The patch price changed according to a binary 
search algorithm. Each binary search had four steps starting at a random price, bounded 
between the IM price ± $20. This search conservatively underestimated willingness-to-
pay. If the participant was willing to pay more than $20 above the IM price, they gave an 
open-ended willingness-to-pay. We asked about three vaccine patch options: self-
administration at home, self-administration with a healthcare worker nearby, and 
healthcare-worker-administration. We repeated these measurements for a hypothetical 
“high-protection” patch offering a 50% smaller chance in getting influenza after 
vaccination. 
 To answer what factors drove acceptance of microneedle patches, we included a 
questionnaire with constructs borrowed from the theory of reasoned action [109]. The 
analysis method is described in Appendix A. 
5.2.6 Quantitative Economic Analysis to Assess Cost-Effectiveness 
 A probabilistic Monte Carlo model explored two potential effects of introducing a 
microneedle patch: reduced influenza illness and improved cost-effectiveness. The model 
only included adults age 18-64. Probability distributions for influenza illness, vaccine 
efficacy, and vaccination costs were taken from an existing publication (Table 5.2 and 
5.3) [7]. The cost of self-administration was set equal to the cost of pharmacy 
administration, which already excluded administrator labor costs. Uncertainty in 
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microneedle patch uptake was generated by bootstrapping this study’s acceptability data. 
Each outcome measure was calculated 100,000 times to estimate uncertainty. 
 
Table 5.2 Inputs of the Economic Model – Illness Parameters and Costs 
Distributions for Predicting  
Coverage and Illness Rates 
Distribution Parameters Source 
Stated preference data bootstrapped n/a 
current 
study 
Standard vaccine effectiveness triangular
1
 a = 0.3, b = 0.9. c = 0.69 1 
Influenza attack rate triangular
1
 a = 0.014, b = 0.155, c = .0066 1 
Current coverage level normal µ = .455, ơ = 0.0114 2 
Current choices of vaccination setting
2
 normal µ’s from chart, ơ = 0.05*µ 2 
Costs – 2010 USD Distribution Parameters Source 
Traditional setting – dose cost constant
3
 11.57 1 
Traditional setting – administration cost triangular
1
 a = 16.31, b = 54.32, c = 24.35 1 
Pharmacy – dose cost triangular
1
 a = 8.46, b = 11.21, c = 9.37 1 




 a = 4.31, b = 10.93, c = 5.14 1 
Mass vaccination – dose cost triangular
1
 a = 3.47, b = 12.53, c = 11.11 1 
Mass vaccination – administration cost  triangular
1
 a = 8.77, b = 10.65, c = 10.24 1 
1 – Triangle distributions were created using data available from the original reference with a = 
minimum, b = maximum, and c = mode. 
2 –The traditional setting included “doctor’s office”, “clinic or health center”, and “hospital.”  
The pharmacy setting included “pharmacy or store” and “other medically-related place.”  The 
mass-vaccination setting included “workplace”, “health department”, “school”, and “other non-
medical place”. A standard deviation of 5% times the mean was applied to all values from the 
original chart.  The sum of the fractions representing each setting is renormalized to 1.0. 
3 – No distribution was provided in the original reference 
4 – Self-administration costs were set equal to pharmacy costs, which did not include administrator labor. 
Sources: 
1. Prosser LA, et al. (2008) Non-traditional settings for influenza vaccination of adults: costs and cost 
effectiveness. Pharmacoeconomics 26(2):163-178. 
2. http://www.cdc.gov/flu/professionals/vaccination/nfs-survey-march2012.htm  
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Table 5.3 Inputs of the Economic Model – Disease Rates 
 
Population Statistics Distribution Parameters Source 
Number, age 18-49 constant 135 million 1 
Number, age 50-64 constant 59 million 1 
% at high risk, 18-49 constant 17.8% 2 
% at high risk, 50-64 constant 34.1% 3 
Illness Statistics
1,2,3
 Distribution Parameters Source 
Hospitalization rate, 18-49, 
healthy triangular
4
 a = 9.8, b = 40, c = 14 4 




5 times rate of healthy individuals 4 




a = 27, b = 232, c = 70 4 




5 times rate of healthy individuals 4 
Death rate, 18-49, healthy triangular
4 a = 0.016, b = 0.68, c = 0.22 4 
Death rate, 18-49, high-risk triangular
4 a = 0.4, b = 3.88, c = 1.11 4 
Death rate, 50-64, healthy triangular
4 a = 0, b = 13.59, c = 3.31 4 
Death rate, 50-64, high-risk triangular
4 a = 0, b = 67.8, c = 16.55 4 
 
1 – Case rate was determined using the influenza attack rate in Table S.3 
2 – The population basis for these rates was the total population minus those protected by the 
vaccine 
3 – All rates given as events per 100,000 
4 – Triangle distributions were created using data available from the original reference with a = 
minimum, b = maximum, and c = mode. 
 
Sources: 




4. Prosser LA, et al. (2008) Non-traditional settings for influenza vaccination of adults: 






 We first determined if participants could correctly apply microneedle patches with 
minimal training. After reviewing an instruction sheet with four sentences of instruction 
accompanied by four pictures, subjects self-administered placebo microneedle patches 
three times, had a placebo microneedle patch administered by study personnel and 
received an IM injection of saline in randomized order.  
  
 
Figure 5.1 A placebo microneedle patch and examples of skin stains applied to evaluate 
usability. (A) A 12x10 mm microneedle array on a 30 mm foam adhesive patch with a 
polyacetal liner that protects the microneedles in packaging. (B) The microneedle array 
under magnification.  Each microneedle is 750 µm long. (C) Gentian violet skin stain. 
(D) Fluorescein skin stain. 
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Given three attempts at self-administration, 95% of participants had a successful 
attempt (63/66, CI: 88-98%, Wilson score interval), confirming our hypothesis that 
participants can correctly apply microneedle patches with minimal training. Fig. 2 charts 
the usability data for each attempt and the best attempt out of three for self-
administration, as well as usability of microneedles administered by study personnel. 
Usability data for four participants were unavailable. Three had unquantifiable 
fluorescein stains; one skipped self-administration when feeling light headed after IM 
injection, and was removed from analysis. 
 
Figure 5.2 Usability of microneedles versus administration attempt.  Attempts one 
through three are participant self-administrations.  Best attempt is the highest percent 
administered from the three attempts.  The control is investigator administration.  The 
dashed line indicates our criterion for a successful patch application.  A random jitter was 
applied to separate overlapping points (±1% on the y-axis). 
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 Participants improved their success rate with each attempt. The success rate for 
the first attempt was 58% (38/63, CI: 45-69%), the second was 70% (45/64, CI: 57-81%), 
and the third was 75% (44/59, CI: 61-85%). Practice with self-administration led to 
significantly improved insertion rates (p = 0.003, n = 57, Friedman’s rank test). 
Experiencing investigator administration before self-administration (due to 
randomization) did not significantly effect microneedle patch usability for participants’ 
first attempts (n = 63, p = 0.09, Mann-Whitney U test). All procedures were well 
tolerated with only very mild, transient erythema. One unrelated adverse event occurred, 
a viral pneumonia case four days after the study. 
5.3.2 Acceptability 
 We next assessed whether more participants would express intent to be vaccinated 
against influenza if offered a microneedle patch. As a baseline data point, 45% of 
participants expressed intent to be vaccinated against influenza during the coming year 
given currently available vaccination methods. This agrees well with 46% influenza 
vaccination coverage reported in the US in 2012 [5]. When participants were offered 
vaccination using a microneedle patch administered by a healthcare professional in 
addition to vaccination by IM injection, intent to vaccinate increased to 62%, which 
corresponds to a suggested coverage improvement of 17% (12/69, CI: 10-28%) (Fig. 3A). 
Among those expressing intent to be vaccinated, 60% preferred the microneedle patch 
and 40% preferred IM injection.  
 We next offered the option to self-vaccinate using a microneedle patch, either at 
home or in the presence of a healthcare worker. Given these additional options, intent to 
vaccinate increased to 64%, representing a 19% (13/69, CI: 11-30%) increase in intent to 
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vaccinate compared to vaccination offered only by currently available methods (Fig. 3B). 
Among those expressing intent to be vaccinated, 45% preferred to self-administer the 
microneedle patch at home, 9% preferred to self-administer the microneedle patch in the 
presence of a healthcare worker, 16% preferred to have a healthcare worker administer 
the microneedle patch, and 30% preferred IM injection.  
 
 
Figure 5.3. Acceptability of microneedles and self-vaccination.  For a patch priced 
equally to an intramuscular injection, participant preference for four vaccination options 
is shown: i) intramuscular injection, ii) healthcare worker (HCW) applies a patch, iii) 
self-administration of a patch with a healthcare worker nearby iv) self-administration of a 
patch at home. The white slice shows participants who would remain unvaccinated.  (A) 
Acceptability of microneedle patches without self-vaccination. (B) Acceptability of 
microneedle patches with self-vaccination. 
 
These data show that offering a microneedle patch dramatically increased intent 
to vaccinate. Although most participants preferred to self-vaccinate, there was only a 
small incremental increase in intent to vaccinate due to offering self-vaccination. These 
data confirm out hypothesis that intent to vaccinate increases if a self-administered 
microneedle patch is offered to participants.  
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To better understand the role of economics in the choices that participants made, we 
evaluated intent to vaccinate as a function of the price differential between out-of-pocket 
cost to the participant for IM injection versus the microneedle patch. As shown in Figure  
5.4, reducing the price of the microneedle patch could further increase intent to vaccinate 
by about 1% per dollar decrease, with an increasing fraction preferring microneedle 
patches.. In contrast, increasing the price of vaccination using a microneedle patch by 
$10-$20 relative to IM injection largely eliminated the increased intent to vaccinate, and 
most participants choosing to be vaccinated switched their preference to IM injection. 
This shows the strong influence of cost on participants’ choice of the microneedle patch 
and their choice to be vaccinated. 
 
 
Figure 5.4 Acceptability of microneedles and self-vaccination, equal effectiveness. 
Participants rated their preference for patch vaccination, no vaccination, or intramuscular 
vaccination vs. patch price.  In each graph, participants are split into those who normally 
intend vaccination (46%) and those who do not.  (A) Acceptability of microneedles 
without self-vaccination versus relative patch price (B) Acceptability of microneedles 




 We carried out an economic analysis to  compare the cost-effectiveness of 
improving coverage with traditional vaccination methods versus improving coverage 
with self-administered microneedle patches using 2010 USD as the basis for comparison. 
We assumed that the median cost of a microneedle patch would be the same as a current 
injectable influenza vaccine, i.e., $10 [7]. The cost of self-administration was set equal to 
the median cost of administration in a pharmacy setting of $6.50, and administration by a 
healthcare worker was set equal to a weighted average cost of $30. 
To reach the coverage levels suggested by the study, additional costs are expected 
because the number of vaccine recipients is increased relatively by 42%.  Unsurprisingly, 
improving coverage with just healthcare provider administration results in a 
commensurate 42% increase in vaccination costs for a healthcare payer. For self-
vaccination, however, our model predicts only a 4% increase in vaccination costs (CI: -15 
to 24%) for the same increase in coverage. This is because self-administration is less 
costly than healthcare worker administration, and the cost reduction extends to those who 
normally intend vaccination but would switch to self-vaccination if it were available. A 
one-way sensitivity analysis (Figure 5.5) identified the traditional setting’s administration 
cost and uncertainty from bootstrapping as the primary unknowns affecting uncertainty.  
Figure 5.6 shows two-way sensitivity analyses for changes in administration costs and 






Figure 5.5 One-way sensitivity analysis for the change in total payer costs after 
introducing self-administered MNs.  To determine which random inputs most affected the 
output, the model was run varying only one parameter at a time.  The bars show the 95% 






Figure 5.6 Two-way sensitivity analyses plotting additional cost for a payer to improve 
coverage by 19%.  Each point is the median of 10,000 iterations. (A) Two-way sensitivity 
analysis for administration costs in the traditional setting (median: $30) and the pharmacy 
setting shown on multiple lines (median: $7). (B) Analysis for administration cost in the 
traditional setting and relative uptake of self-administration among microneedle patch 
users compared to the uptake measured in this study (relative to 85% uptake for new 
vaccinees and 72% for existing vaccinees, +15% means multiplying by 1.15x).  Both 
figures illustrate that administration cost in the traditional setting is a major factor in the 
economic evaluation of self-administration.  The cost of vaccination in the pharmacy 
setting, which was later set as the cost of self-administration, simply shifts the curve up 
or down.  The effect of the self-adminsitration uptake rate, however, is proportional to the 
traditional setting administration cost.  The HCW only line shows the additional cost of 
increasing coverage without self-administration. Values less than 0% represent an 




Using the model, we also determined that a 42% increase in vaccination coverage 
for a typical influenza season could lead to 1.6 million fewer cases of influenza, 22,000 
fewer hospitalizations, and 930 fewer deaths among adults age 18-64, who were the 
subject of this study.  Coverage increases among children and the elderly could reduce 





 We compared the pain of microneedle administration and IM injection for 
participants who administered their first patch correctly (Figure 5.7). The median pain 
scores, out of 100, were 1 for self-administration, 3 for investigator administration, and 
14 for IM injection. Statistical analysis showed microneedle patch administrations were 
significantly less painful than IM injection (repeated measures ANOVA: p<0.0001; self-
administration vs. IM, p<0.01, investigator-administration vs. IM, p = 0.02).
 
Figure 5.7 Paired comparison of pain scores.  Points show paired comparisons of VAS 
pain scores (scale 0-100) for participants who successfully administered their first 
microneedle patch.  The microneedle patch was significantly less painful than the IM 




5.3.5 High Effectiveness Patch: Acceptability and Cost-Effectiveness 
 Because microneedles may offer improved immunogenicity due to vaccine 
targeting to dendritic cells in skin [48], we studied the impact of a hypothetical high-
effectiveness patch (50% relative effectiveness improvement) on coverage and cost-
effectiveness. The high-effectiveness patch improved suggested coverage levels further 
(Figure 5.8): 49% relative coverage improvement for the microneedle patch without self-
administration (46/69 vs. 31/69) and 62% coverage improvement for a self-administered 
patch (50/69). We compared the cost-effectiveness of self-administration and high-
effectiveness patches by calculating the reduction in average cost per case averted for 
different vaccination scenarios.  Self-administered microneedle patches could reduce the 
median cost per case averted from $690 to $510.  A high-effectiveness patch without 
self-administration could reduce that number to $540.  With self-administration and high 






Figure 5.8. Acceptability of microneedles and self-vaccination, high-effectiveness 
patches. (A) Acceptability of microneedles without self-vaccination versus relative patch 
price. (B) Acceptability of microneedles with self-vaccination versus relative patch price. 
 
 
Figure 5.9 Comparison of cost-effectiveness histograms for different self-vaccination 
scenarios.  (A) Self-adminsitration permitted, patch has same effectiveness as standard 
intramuscular injections.  (B) Self-administration not permitted, patch has improved 
effectiveness.  (C) Self-administration permitted, patch has improved effectiveness.  
Without self-administration or effectiveness improvement there is no reduction in cost 
per case averted in this model. 
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5.3.6 Factors Affecting Microneedle Patch Uptake 
 We measured psychosocial indicators of microneedle acceptability with 
constructs from the theory of reasoned action [109].  An exploratory principal 
components factor analysis yielded four primary factors covering 66% of the total 
variance among subjects (see Table 5.4).  The four factors were: attitude towards 
microneedles, normative approval, behavioral beliefs, and outcome evaluations. 
Normative approval measured participants’ perceived approval of doctors, family, and 
friends for microneedle use. Behavioral beliefs measured the perceived convenience and 
reliability of patches. Outcome evaluations related to physical side effects. 
 Each participant had a normalized score for each factor. We regressed these 
scores to a binary measure of whether a participant would choose a microneedle patch 
offered at the same price as an intramuscular injection, based on the acceptability data. 
The significant predictors of uptake were behavioral beliefs about usability and reliability 
(p = 0.001) and normative approval (p = 0.02).  This indicates that acceptability of 
microneedles depends on convincing patients that microneedles are convenience and 
reliable to use and that doctors, family and friends approve of microneedle vaccination. 
Positive attitude towards microneedles (p = 0.06) and outcome evaluations (p = 0.4) 
positively correlated with uptake, but were not statistically significant, indicating that the 
pain reduction associated with microneedles was not important to acceptability.  
 The questionnaire items themselves also produced interesting results.  Every 
participant agreed or strongly agreed that microneedle patches were easy to administer, 
and no participant disagreed that microneedle patches could administer flu vaccine 
reliably. 
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Table 5.4. Items Included in Behavioral Questionnaire 
 
Factor Mean SD Min Max Loading 
Behavioral Beliefs (α = 0.845)       
1. The vaccine patch can administer flu vaccine 
reliably. 
2.84 0.70 2 4 0.57 
2. I think a vaccine patch could offer as much 
protection against the flu as an injected 
vaccine. 
3.06 0.84 1 4 0.74 
3. Putting a vaccine patch on my arm at home is 
[much less safe, less safe, as safe, safer, 
much safer] compared to an injection from 
a nurse or doctor. 
2.35 0.95 0 4 0.72 
4. A vaccine patch will be more convenient for me 
than an injection. 
3.38 0.62 1 4 0.65 
5. Overall, vaccine patches will help me save time 
compared to injections. 
3.30 0.75 1 4 0.66 
6. Vaccine patches are easy to use. 3.54 0.50 3 4 0.63 
7. I can easily tell if I put a vaccine patch on my 
arm the right way. 
2.86 0.99 1 4 0.60 
 
Outcome Evaluation (α = 0.806) 
     
1. A vaccine patch will lead to less bleeding than 
an injection. 
3.10 0.97 0 4 0.71 
2. A vaccine patch will lead to less skin damage 
compared to an injection. 
2.61 1.09 0 4 0.81 
3. A vaccine patch will lead to less risk of injection 
compared to an injection. 
2.65 1.04 0 4 0.78 
 
Normative Approval (α = 0.845) 
     
1. My family will think it’s a good idea if I choose 
a vaccine patch instead of an injection. 
2.68 0.88 1 4 0.82 
2. Important people in my life will approve if I 
choose a vaccine patch instead of an 
injection. 
2.46 0.92 0 4 0.60 
3. My friends will approve if I choose a vaccine 
patch instead of an injection. 
2.81 0.77 1 4 0.79 
4. My doctor will approve if I choose a vaccine 
patch instead of an injection. 
2.51 0.76 1 4 0.66 
5. Important people in my life would suggest that I 
get a vaccine patch instead of an injection. 
2.65 1.04 0 4 0.76 
 
Attitudes (α = 0.904) 
     
1. I think that vaccine patches are an improvement 
over injections. 
3.26 0.80 0 4 0.79 
2. I prefer a vaccine patch over an injection. 3.20 0.80 0 4 0.87 
3. Compared to injections, vaccine patches have 
benefits that are important to me. 
3.01 0.72 0 4 0.84 
4. I like vaccine patches more than injections. 3.19 0.86 0 4 0.82 
5. Putting on a vaccine patch will be less painful 
than getting an injection. 
3.20 0.87 0 4 0.60 
6. Compared to vaccine patches, injections have 
drawbacks that matter to me. 
 




This study aimed to show that self-administered microneedle patches are usable, 
acceptable, and potentially cost-effective. Concerning usability, almost all participants 
were able to self-administer microneedle patches with minimal assistance. In previous 
studies, microneedles have been applied to thousands of human subjects, mostly by study 
investigators [9]; this study showed reliable self-administration in a relatively large, 
diverse population. Here, many participants needed multiple attempts and instruction to 
push harder in order to successfully self-administer microneedles. Because of this, we 
think mechanical applicators may be necessary for reliable self-vaccination with 
microneedles. Additional work is needed to validate vaccine delivery and immunological 
responses after microneedle self-administration, because the staining method use here 
only demonstrated microneedle puncture.  
 For acceptability, we showed that more people would intend vaccination if a self-
administered microneedle patch were available. Although self-administration was 
preferred over all other methods, it was not critical to increasing coverage; offering 
microneedle patches without self-vaccination led to most of the suggested coverage 
improvement. Consistent with these findings, previous studies showed that intradermal 
vaccination with a very small hypodermic needle was preferred [57, 205] and expected to 
expand vaccination coverage [204] compared to IM injection.   
 The quantitative acceptability analysis suggests that offering a microneedle patch 
alone was sufficient to convert 17% of participants to willing vaccinees, while the added 
convenience of self-administration had only an incremental additional effect on intent to 
vaccinate. However, in the behavioral analysis, the scale measuring perceived 
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convenience of patches was the most significant factor predicting microneedle 
acceptability.  This suggests that self-vaccination may contribute more to coverage 
improvements in real vaccination situations because the convenience benefit will be 
tangible rather than hypothetical, as it was in our questionnaire.. 
 Considering cost-effectiveness, we predict that a self-administered influenza-
vaccine patch is an efficient and potentially cost-saving way to improve vaccination 
coverage.. The ability to administer more vaccine at lower cost came from reducing the 
cost of vaccine administration by healthcare personnel. Our study showed that 
participants widely preferred self-administration with microneedles over all other options, 
suggesting that these cost savings will come as a natural consequence of introducing 
microneedle patches that can be self-administered. We used the healthcare payer’s 
perspective for a conservative estimate of cost-effectiveness.  Including reduced patient 
time for vaccination from a societal perspective could add to the expected savings for 
self-vaccination. 
Our evaluation assumed the microneedle patch and traditional vaccine could be 
sold for the same price, which is possible given the low cost of microneedle technology 
and the large economy of scale associated with influenza vaccine manufacturing [8]. We 
will need to revisit our economic analysis as microneedle manufacturing costs become 
clearer and as the landscape changes for vaccine presentation (e.g., prefilled syringes) 
[139] and vaccination settings [5].  
In addition to reducing the cost of vaccination to the healthcare payer, the 
increased coverage resulting from introducing a microneedle patch for self-vaccination 
should lead to additional advantages, such as reduced patient time to be vaccinated, 
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increased productivity in schools and workplaces due to less illness, fewer 
hospitalizations, and fewer deaths. Potential negative implications include administration 
mistakes by patients and difficulty registering self-vaccinations into immunization 
information systems.  
Our future research will focus first on translation. We need to improve insertion 
devices to approach 100% reliable insertion on the first attempt, reproduce acceptability 
results with larger and broader populations, conduct clinical trials on the immunogenicity 
and safety of self-vaccination, and scale up manufacturing. Regulatory approval will 
require addressing safety concerns like anaphylaxis and syncope and legal topics such as 
waste disposal, mailing of biologicals, over-the-counter policy, and the Vaccine Injury 
Compensation Program. Approval for self-administered influenza vaccines seems 
attainable since oral typhoid – a multi-dose, live vaccine that must be refrigerated – is 
also approved for self-administration [12].   
 The primary limitations of this study are small sample size, volunteer bias, stains 
that indicate microneedle insertion rather than vaccine delivery, use of stated preference 
for willingness-to-pay, potential bias due to experience with self-administration, and 






6.1 Fabrication of Hollow Metal Microneedles 
 This research presented, for the first time, a fabrication process based on 
sacrificial micromolding and selective electrodeposition to produce side-opened, sharp-
tipped, hollow, metal microneedles. The resulting microneedles were shown to be 
sufficiently strong to permit reliable insertion into skin without failure and to enable 
injection into skin in vitro and in vivo. The micromolding approach is expected to enable 
low-cost, mass production of microneedles, which is an advance over prior methods that 
relied on direct fabrication of microneedles or more complicated molds. With additional 
research and development, this microneedle design could enable simple, reliable 
intradermal injections.  
6.2 Insulin Delivery using Microneedles to Type 1 Diabetic  
Children and Adolescents 
This is the first study of intradermal insulin delivery using microneedles in type 1 
diabetic children. The study shows that microneedle administration of insulin in children 
resulted in less needle insertion pain and faster insulin onset and offset kinetics.  The 
reduction in pain may increase compliance with insulin therapy, especially in needle-
phobic children.  The accelerated pharmacokinetics may be improve closed-loop insulin 
therapy, which requires rapidly responsive insulin delivery to maintain tight glycemic 
control. 
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6.3 Usability, Acceptability, and Cost-Effectiveness of Microneedle Patches for Self-
Vaccination against Influenza 
We conclude that microneedle patches for self-vaccination against influenza are 
usable, acceptable, and cost-effective. Almost all participants were able to apply 
microneedle patches with minimal training. Intent to vaccinate increased from 45% to 
64% if a self-administered microneedle patch was offered to participants. Modeling 
predicted that offering self-vaccination against influenza adds only 4% to total 
vaccination costs even though coverage increases by 42%. Microneedles were reported to 
be less painful than IM injection, a hypothetical high-effectiveness patch offered for self-
administration increased intent to vaccinate by a relative 45%, and perceived 
convenience, reliability, and normative approval were found to be the main factors 
affecting microneedle patch uptake by participants. This first study on self-vaccination 
for coverage and cost-effectiveness improvements should motivate further research and 







7.1 Recommendations for Hollow Microneedle Design 
A key remaining challenge in hollow microneedle design is to determine if side-
opened microneedles reduce the pressure of delivery compared to microneedles with 
axial lumens.  An adequately controlled experiment has not been performed.  This is 
important because reduced pressure will reduce the demands on the pumping mechanism 
[69] and because reduce pressure is expected to reduce pain associated with infusion [67]. 
Another challenge is designing microneedles to integrate with discrete, wearable insulin 
pumps and stay in a patient’s skin for multiple hours’ use. This is important because the 
full potential of microneedles will be realized by a patch-like system for infusion into 
skin, as opposed to simply mounting microneedles onto conventional syringes, as is 
currently done.  
7.2 Recommendations for Insulin Delivery in Human Subjects 
 Four recommendations came from the insulin delivery study in type 1 diabetic 
children.  First, because microneedles were more painful during infusion compared to 
subcutaneous catheters, research should focus on reducing the pain of intradermal 
injections. This can be accomplished by adding the spreading enzyme hyaluronidase [67], 
reducing the flow rate, using multiple injections, or using an optimzied programmed flow 
rate pattern to infuse liquids into skin at minimal pressure. Second, long-term studies 
should be conducted to examine the acceptability of microneedles and their effect on 
injection compliance in adults and children.  Improving compliance is a major reason for 
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investigating microneedels for insulin delivery, and compliance can be quantitatively 
assessed by measuring HbA1C levels after experimental use of a device [179].  Third, 
research should focus on accelerating the pharmacokinetics of insulin delivery even 
further by using insulin analogs, applying local heating, or distributing the bleb across 
multiple injection sites to facilitate protein uptake.  Finally, studies in animals and 
humans should test whether microneedle-based insulin delivery can truly enable closed-
loop insulin delivery.  It is hypothesized that the rapid onset and offset of insulin delivery 
will facilitate automatic control of plasma glucose levels, but this has yet to be tested. 
7.3 Recommendations for Self-Vaccination 
Future research on self-vaccination should focus on solving problems on the path 
to regulatory approval and then expand self-administration to other vaccination programs.  
The problems on the path to approval include improving the first-attempt reliability of 
self-administration by using applicators, confirming successful drug or antigen delivery 
after self-administration, validating the acceptability results in a broader population, 
validating potential compliance with self-vaccination, addressing legal issues like waste 
disposal and prescription policies, and addressing safety issues like anaphylaxis and 
syncope. 
Expanding self-vaccination beyond influenza vaccines could include evaluating 
self-administration of other voluntary vaccines, evaluating administration by minimally-
trained vaccinators in the developing world, and developing novel prime-boost regimens 




7.4 General Recommendations for Microneedles 
 This section considers recommendations for microneedle research beyond the 
scope of this particular dissertation.  Future microneedle work will have three foci: 
developing microneedles as marketable products for well-studied clinical indications (e.g. 
insulin delivery), applying microneedles to known drug delivery problems, and 
developing microneedles for new applications. 
 Developing microneedles as marketable products encompasses the obvious but 
difficult work of finalizing a product design and obtaining regulatory approval for a 
disruptive technology. 
 For applying microneedles to known problems, examples include immunization 
of the young and the old, studies of the efficacy of heterologous prime-boost 
immunizations using two different sites of antigen delivery[212, 213], and comparative 
effectiveness studies comparing the efficacy and feasibility of multiple vaccination 
methods. 
 Developing new applications for any device is a challenge.  New applications for 
microneedles should draw from the core advantages of microneedles over other drug 
delivery methods: targeting to specific tissues; improved patient compliance; 
administration by patients or by minimally trained personnel; delivery of larger doses 
than the transdermal route; delivery of more consistent doses than the mucosal route; and, 
ability to use complex delivery profiles based on formulation, programmed pressure 
sources, or user input [214].  One application may be microneedles for blinding trachoma 
if the disease is not eliminated by 2020 as expected [215].  Microneedles would be useful 
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for targeting azithromycin to the conjunctiva to reduce dose requirements and community 
antibiotic resistance, while also enabling administration by minimally trained personnel. 
Microneedles may be useful for treating and preventing other infections with 
antimicrobials, as sustained transcutaneous delivery may keep antimicrobial 
concentrations above minimum inhibitory concentrations [216] with minimal patient 
effort required; the key challenge may be storing and delivering sufficient doses of 
antimicrobials.   
Diagnostic applications of microneedles seem promising and may even be useful 
in epidemiological research by permitting quick identification of target individuals [217].  
Microneedles will likely find non-medical (commercial and military [218]) applications 
for on-demand or automated drug delivery.  Finally, I expect the skin microbiome will 
garner some attention from microneedle researchers for the possibility of preventing and 






A.1 Molding Process for Hollow Metal Microneedles 
A.1.1 Quantifying Percent of Dye Delivered Intradermally Using ImageJ 
 Fluorescent images of histological cross-sections were opened in ImageJ, and 
split into red, green, and blue channels (Image  Color  Split Channels).  Only the red 
channel was kept for analysis.  The free-hand selection tool was used to select 
background areas, dermis areas, and non-dermal-tissue areas identified in light 
microscopy images.  Figure A.1 shows an example background selection on a red 
channel image. 
 
Figure A.1 Selecting a background region on a red channel image 
  
 For each region selected, after clicking on (Analyze  Measure), ImageJ 
provides an area and an average intensity.  The area and average intensity can be used to 
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    Eq. A.1 
  
In this equation, A represents the area of a particular region, I represents the mean 
red intensity of a particular region, ID is intradermal, and nonID is non-intradermal 
tissue. 
 
A.2 Insulin Delivery Using Microneedles to Type 1 Diabetic Children and 
Adolescents 
A.2.1 Regressing Insulin Concentrations to a Compartment Model Equation 
 Insulin concentration over time for each participant was fit to a one-compartment 
model assuming a constant absorption rate from an injection site and a constant 
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Here, I is the concentration of insulin at the injection site (µU/ml), I0 is the dose of insulin 
delivered (µU), ka is the absorption rate (min
-1
), ke is the elimination rate (min
-1
), t is time 
(min), and C is the concentration of insulin in the systemic volume (µU/mL). The 
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solution for C(t) is given below: 
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       Eq. A.6 
where, and A is a scaling parameter (µU/mL) equal to I0 divided by the systemic volume.  
 Insulin concentrations were fit using proc nlin in the SAS software package.  Data 
for each condition for each participant was put in manually into a variable called 
insulinC.  Example SAS code for data entry and regression are shown below: 
data insulinC; 








90  37.8 
105  33.5 
120 26.1 
150 20.8 






proc nlin data=insulinC; 
  parameters  A=200 ka=.01 ke=.03; 
  model conc   = A*ka/(ke-ka)*(exp(-ka*time)-exp(-ke*time)); 
run; 
 
Occasionally the model would not converge in situations where ka and ke were 
nearly equivalent.  In these cases, A was removed as a regression parameter and manually 
iterated until the squared error of the model was minimized.  The final output for the 
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regression was values for A, ka, and ke for each experimental condition for each 
participant. 
 
A.2.2 Calculating Onset and Offset Times 
 In Chapter 4, insulin onset time was defined as the time to reach the peak insulin 
concentration, and insulin offset time was defined as the time to fall back to half the peak 
concentration.  These values were calculated using the A, ka, and ke values from 
regression analysis.  The time to peak concentration can be setting the derivative of the 
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       Eq. A.11 
 
 The time to peak concentration depends only on the rate constants in this 
simplified model.  There is no dependence on the size of the dose delivered.  For cases 
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Plugging tmax, the time to peak concentration, into Eq. A.6 provides the peak 
concentration, Cmax: 
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          Eq. A.19 
 
 The insulin offset time was solved for numerically using Microsoft Excel’s solver 
function.  The value for t in Eq. A.6 was iterated until the concentration from that 
equation was 0.5*Cmax.  Because 0.5*Cmax and Eq. A.6 have the same linear relationship 
with A, A can be divided from both sides of the equation. Because A does not remain in 




A.2.3 Calculating Area Under the Insulin Curve 
 The area under the insulin curve (AUC) is a measurement for comparing the 
bioavailability of two insulin delivery methods.  It is the integral of insulin concentration 
vs. time.  The integral can be approximated using the trapezoid rule, or calculated exactly 
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          Eq. A.25 
 
 The exact integral does not depend on the absorption rate.  Therefore, delivery 
methods with different absorption rates such as intradermal and subcutaneous delivery 
should have similar bioavailabilities according to this model. 
  
 95 
A.3 Usability, Acceptability, and Cost-Effectiveness of Microneedle Patches for Self-
Vaccination against Influenza 
A.3.1 Patch Fabrication 
 Microneedle patches were made from four parts: a stainless steel microneedle 
array, an adhesive foam backing, a polyacetal packaging piece, and a paper/silicone liner.  
Bending needles, cutting parts with a CO2 laser, and cleaning parts took place in an area 
of the lab portioned off by plastic drapes.  The remainder of the processes took place in a 
clean laminar flow hood with lab personnel wearing clean disposable gowns, sleeve 
covers, and gloves. 
A.3.1.1 Bending the Arrays Out-of-Plane 
Stainless steel microneedle arrays were purchased from a contract manufacturer 
and bent 90° out-of-plane.  Four joined arrays were loaded into a laser-cut acrylic mold 
with holes positioned below the needles.  The arrays were taped into place using a 
medical grade cloth tape.  A 25 gauge, 5/8” long sterile needle attached to a 3 mL syringe 
was used to press each needle out-of-plane.  The partially bent arrays were placed under a 
microscope, and a number-11 scalpel blade was used to bend rows of needles to 90°.  
Groups of four joined arrays were then cut into single arrays using stainless steel scissors.  
Microneedle arrays were cleaned three times in isopropyl alcohol prior to assembly. 
A.3.1.2 Cutting out the Backing 
 30 mm adhesive foam backings were made from a medical grade adhesive foam 
material (TM9942, MacTac, Stow, OH).  The adhesive foam backings were cut out using 
an arbor press (2402A11, McMaster Carr, Atlanta) modified to have a hollow punch tool 
(66004, Mayhew Tools, Turner Falls, MA) placed on the piston.  
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A.3.1.3 Cutting Out the Packaging Material 
Polyacetal packing pieces were made using a CO2 laser to cut 3/32” polyacetal 
sheeting.  The shape is shown in Figure A.2 in black.  The shape was designed to be cut 
out using only straight lines and circles in order to accommodate a paper/silicone liner, 
which could only be cut using scissors and the hollow punch tool on the arbor press.  The 
shape is defined as a 45x30 mm rectangle with multiple circular cuts.  Two 30 mm 
semicircular cuts defined a rounded shape for the packaging.  A partial 24 mm circular 
cut defined a place for user to pick up the patch, and a 16 mm hole provided a window 
where the needles sit surrounded by polyacetal packaging.  The polyacetal pieces were 
cleaned three times in isopropyl alcohol before assembly. 
 
 
Figure A.2 Diagram showing packaging and liner shape for microneedle patch and the 
circles used to define the shape using a hollow punch tool 
 
A.3.1.4 Cutting out the Liner 
 A liner material is necessary because the adhesive foam backing and the packing 
material adhere too strongly to each other.  A liner material is cut out from the liner 
material from the adhesive foam backing (TM9942, MacTac, Stow, OH) with a thin 
double-stick adhesive (1522, 3M, Minneapolis) applied beforehand. 
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A.3.1.4 Assembly and Sterilization 
 Each liner is adhered to a polyacetal packaging piece using the double-stick 
adhesive on the liner.  An adhesive foam backing is set into place on the liner side of the 
polyacetal packing.  Then, a microneedle array is set into the 16 mm window of the 
packaging piece and pressed into place with tweezers.  Fig 5.1A shows an example 
complete device. 
 Completed devices were double-bagged in manually sealed sterilization pouches 
(Thermo Fisher Scientific, Waltham, MA).  Bagged devices were placed into cardboard 
shipping boxes with packaging paper added to space devices evenly for ethylene oxide 
sterilization.  Boxes were sent to Steris Isomedix (Minneapolis, MN) for two ethylene 
oxide sterilization cycles. 
 
A.3.2 Venue Recruiting: List of Locations and Materials Used 
 Participants were recruited from publically accessible venues.  A list of venues for 
each month was prepared beforehand containing random venues (available at any time 
during a month) and non-random venues (special events only available on certain dates).  
The list of venues included sites used by Emory University’s Hope Clinic for other 
studies, sites recommended by the Hope Clinic to attain a good geographic distribution of 
sites within 5 miles of the Georgia Tech campus, non-random sporting events, and non-
random events collected from Atlanta festival websites and other sources.  Specific 
locations could have more than one available timeframe, but each location would only be 




Table A.1 Venue Pool used in October 2011 
MARTA - Buckhead MARTA - Oakland City 
MARTA - Lindbergh MARTA - West Lake 
MARTA - Arts Center MARTA - Ashby 
MARTA - Midtown MARTA - Vine City 
Sweetwater Brewery Centennial Olympic Park Area 
Clifton and North Decatur Starbucks Pittman Park Rec Center 
Street Food Thursdays - 10th and Peachtree Windsor Super Market  / Dunbar Center 
1010 Midtown building area Sweet Auburn Curb Market 
Piedmont Park Ria's Bluebird / Mibarrio 
MARTA - Lenox Thumbs Up Diner 
Flying Biscuit / Caribou Nick's Greek Food to Go downtown 
Ponce + Myrtle (Mary Mac's Tea Room) MARTA - North Avenue 
Linden and Peachtree MARTA - Civic Center 
Ansley Park Shopping Center MARTA - Peachtree Center 
Peachtree between Collier and Montclair MARTA - Five Points 
Fellini's Buckhead near Episcopal Cathedral MARTA - East Lake 
Publix or CVS at Lindbergh and Cheshire Bridge MARTA - Edgewood/Candler Park 
Coffee Shops near Peachtree and 17th MARTA - Inman/Reynoldstown 
Virginia and Highland Intersection MARTA - King Memorial 
Highland and University (Yoforia, etc.) MARTA - Georgia State 
Sage Hill Shopping Center Grant Park / Zoo 
High Museum / Colony Square lunch time Little 5 Points 
Atlantic Station Candler Park Neighborhood 
11th and Howell Mill East Atlanta, Main Intersection 
 Taqueria del Sol on Howell Mill Edgewood Shopping Center 
10th and Atlantic MARTA - Bankhead 
Paces Ferry Plaza Shopping Center Inman Park 
Howell Mill + Collier Center for Black Women's Wellness 
Nuevo Laredo Cantina Purple Door Salon 
Octane Coffee Bar/Five Seasons Woodruff Park 
Bobby Jones Golf Course/Tennis Center Dannemann's Restaurant 
Firehouse subs / Sublime Donuts Sugar Hair Studio 
Carvers Country Kitchen Little 5 Points Halloween Festival 
Redbrick (ABC) brewing company Atlanta Pride Festival 
MARTA - Garnett Taste of Atlanta 
MARTA - West End Philips Arena Show or Basketball Game 
Georgia Tech Football Game Fox Theater 




 A calendar was prepared each month according to previously published 
procedures [221].  We compiled potential venue timeframes into a .csv file, and created a 
Visual C# program to generate a calendar according to these procedures.  In the .csv, the 
first column was the venue name, the second column was the date (an abbreviation such 
as ‘tu’ for Tuesday or a decimal such as 10.08 for October 8), the third and fourth 
columns had beginning and ending times for recruiting at that venue listed in military 
time format (e.g. 1500 for 3:00 PM).  The program provided a primary and two alternate 
venues for each day of the month.   
We approached people at recruiting sites with a standard message: 
“Hello, I’m recruiting for a study at Georgia Tech. Can I talk with you for 
a minute?  We’re studying a new type of skin patch and comparing it to an 
intramuscular injection. This is a device comparison study, so there are no 
drugs involved. You would come to Georgia Tech for an hour, and if 
you’re not a Georgia Tech student or employee, you will be given $35 for 
your participation. The study involves putting the patch on yourself, have 
us put it on you, and have us give you an injection. We will apply a dye to 
test whether the patch was applied correctly. You would also answer some 
questions about pain you felt, your preferences for different procedures, 
your thoughts on how to improve the skin patch, your experience with flu 
vaccines, and your personal characteristics, such as your age and gender. 
If you are interested, I would like to try to schedule you for an 
appointment. We can only schedule you for an appointment if you meet 
these requirements [Investigator shows exclusion criteria]. I would like to 
collect your first name, last initial, phone number, and e-mail address as 
well.”  
 
If a person was interested, we collected their name and phone number and 
provided them with a card, an appointment time, and a map to the study location at 





Figure A.3 Business card used during venue based recruiting 
 
A.3.3 Usability Analysis 
 Participant skin sites were stained after microneedle insertion in order to quantify 
the usability of microneedle patches.  Example stains are shown in Figure 5.1C and 
Figure 5.1D.  Some factors affecting quantification included blood spots or other 
indeterminate spots and unquantifiable images.  Some images were unquantifiable due to 
excess staining with fluorescein or insufficient lighting to observe the fluorescent spots 
(e.g., when the batteries to the lighting did not provide sufficient power).  The formula 










       Eq. A.25 
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 An example image with indeterminate blood spots considered uncountable is 
shown in Figure A.4.  An example unquantifiable image is shown in Figure A.5. 
 
 
Figure A.4 Example stain with uncountable, indeterminate blood spots 
 
Figure A.5 Example unquantifiable fluorescein stain 
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Some original images of fluorescein stains were dark and difficult to quantify 
without modifying the color balance.  The color balance on these images was linearly 
modified over the whole image in order to visualize the insertion sites.  An example of 
this modification is shown in Figure A.6 and Figure A.7. 
 
 
Figure A.6 Fluorescein stain before color balance adjustment 
 
 
Figure A.7 Fluorescein stain after color balance adjustment 
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A.3.4 List of Questionnaire Materials 
 Participants viewed movies and answered questionnaire items using an adaptive 
questionnaire program developed in Visual C# (Microsoft, Redmond, WA).  Movies 
were created using Corel Visual Studio Pro (Ottawa, ON). 
A.3.4.1 Introductory Movie 
 Before beginning experiments, participants viewed an introductory movie with 
the following script: 
“Welcome to Georgia Tech’s device comparison study.  We appreciate 
you taking your time to participate.  Here is an overview of what to expect 
today: First, for the device comparison study, you will be comparing two 
medical devices: (1) a standard needle and syringe, and (2) a new type of 
skin patch.  You will experience three different ways that these devices 
can be used.  No drugs or vaccines will be used in this study, however. We 
are only studying your experience with the devices.  The three different 
administration methods we’re studying are: (1) we give you an injection, 
(2) we put the skin patch to you, and (3) you put the skin patch to yourself. 
You will be given three skin patches to apply to yourself.  You will 
experience these methods in a random order. After each method you will 
be asked to rate your pain on a sliding scale.  After the skin patch 
insertions, we will be applying a dye to your skin to determine whether the 
patch was successfully administered.  This part of the study should not 
take more than 20 minutes.  After the device comparison study, you will 
be asked to complete a short questionnaire related to your experience and 
what you think about these devices being used for flu vaccines.  The 
survey should not take more than 30 minutes to complete.  As we move 
on, please answer each question as honestly as possible.  You may choose 
not to participate, and you may skip any question you do not wish to 
answer.  However, please try to answer every question.  Thank you again 
for your participation.  Let’s begin.” 
 
 
A.3.4.2 Pain Assessment 
Volunteers rated the pain associated with the procedures in the study using a sliding bar 
ranging from “No pain” to “Worst Pain.”  Procedure Labels: [when we gave you an 
injection, when we put the vaccine patch on you, when you put on the vaccine patch].  
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A.3.4.3 Definition Movies 
 Movies were presented to participants to define terms in the questionnaire. 
 Flu/Influenza: “The flu is a disease that affects people primarily in Fall and Winter, 
and a different form of this disease comes back every year.  A vaccine that helps 
prevent the flu is available every year.” 
 Injection: “An injection is the delivery of fluid using a needle and syringe.  An 
injection is the most common way to deliver the seasonal flu vaccine.” 
 Vaccine Patch: “The vaccine patch is a device that can contain vaccine that dissolves 
in the skin. Vaccine patches are being studied as a method for delivering flu 
vaccines.” 
 Healthcare Worker: “A healthcare worker is a nurse, a doctor, or a pharmacist who 
can deliver a vaccine to you.  All current flu vaccines are given by healthcare 
workers.” 
 Self-Administration: “People may be able to deliver vaccines to themselves in the 
future using technology like the vaccine patch.  You may be able to purchase a 
vaccine at a pharmacy or grocery store or from an online store and deliver it to 
yourself at home.  Another option is self-administration of a vaccine with a healthcare 
worker nearby who will make sure you performed the vaccination correctly.  This 
could be done at pharmacies, workplaces, community centers, or any other place 
where flu shots are typically given.  Self-administration is expected to be more 
convenient that healthcare worker administration because vaccines will be available 
in more locations and there will be less waiting in lines.  Also, self-administration at 
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home could be done at any time during the day rather than only when a healthcare 
worker is available.” 
 
A.3.4.4 Demographic Questions 
 What is your gender? [Male, Female, Transgender] 
 What is the highest level of education you have completed? [Have not completed 
kindergarten, K-8 grade, 9-11 grade, High School Graduate / GED, 
Technical/Vocational or Associate’s Degree, Bachelor’s Degree, Master’s Degree, 
Doctorate Degree] 
 How would you describe your race/ethnicity? [Asian/Asian American/Pacific 
Islander, Hispanic/Latino/Chicano, African American/Black, Caucasian/White, 
Native American/American Indian/Alaskan Native, Multiracial] 
 What is your annual household income (combined income of all members of your 
household)? [Less than $20,000, $20,001-40,000, $40,001 - $60,000, $60,001 - 
$80,000, $80,001 - $100,000, more than $100,000] 
 What is your age in years? [open ended] 
 
A.3.4.5 Questions on Flu Vaccine Experience (Adaptive) 
 Have you ever had a case of the flu? [Yes, No, Don’t Know] 
 Have you received a flu vaccine in the past 3 years? [Yes, No, Don’t Know] 
o If yes: Approximately what price did you pay for your flu vaccine? [open 
ended] 
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o Otherwise: Approximately what price would you have to pay for a flu 
vaccine? [open ended] 
 Do you intend to get a flu vaccine in the next 12 months? [Yes, No] 
 
A.3.4.6 Movie Explaining Stated Willingness-to-Pay Section 
 Before the next section of the questionnaire, the stated willingness-to-pay-section, 
participants were shown a movie explaining how to respond to questions in that section.  
The script of the movie was: 
“In the next section, you will be asked about your preference for 3 
different vaccination methods.  On the screen you will be told that you 
can get a flu vaccine by injection for a certain price, choose not to get a 
flu vaccine at all, or choose the option below.  The starting price for each 
vaccination method is random, and it changes based on your answers.  
Please click a button indicating whether you would or would not accept 
the displayed option.  In total, there are 12 questions in this section.” 
 
 
A.3.4.7 Stated Willingness-to-Pay Questions (Adaptive) 
Volunteers express their willingness-to-pay for the following scenarios relative to 
a control of intramuscular injection or no vaccination: use a vaccine patch at home, use a 
vaccine patch with a healthcare worker nearby, and have a healthcare worker apply a 
patch to you.  For each scenario, there were four questions based on a binary search 
algorithm to find the participants maximum willingness-to-pay value.  The range of 
prices search went from (base cost - $20) and (base cost + $20), where “base cost” is the 
minimum of $25 or the volunteer’s reported price they pay for their flu shot.  The starting 
guess was a random number between (base cost - $12) and (base cost + $12), and all 
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prices shown to the participant were rounded to the nearest dollar.  An example frame 
from this section of the questionnaire is shown in Figure A.6. 
 
 
Figure A.6 Example Frame from Willingness-to-Pay Questionnaire 
 
If a participant accepted a patch option at every price shown, they were asked to list their 
open-ended willingness to pay as shown in Figure A.7. 
 
 
Figure A.7 Example Frame for Open-Ended Willingness to Pay 
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A.3.4.8 Stated Willingness-to-Pay for High Protection Patches 
 Participants repeated the stated willingness-to-pay section to evaluate a 
hypothetical “high-protection” (high-effectiveness) vaccine patch in different use 
scenarios.  The difference in protection level was described in a movie with the following 
script: 
“Receiving a flu vaccine does not guarantee protection against the flu.  A 
few vaccine recipients will still get the flu.  Newer vaccines may offer 
better protection against the flu.  For new, high protection vaccines: 
assume you would have a smaller chance of getting the flu, a 50% smaller 
chance.  Please answer 12 more preference questions, this time, all of the 
options will offer high protection.” 
 
 
A.3.4.9 Preferred Method 
 After the stated willingness-to-pay section, participants chose a preferred method 
of vaccination out of the following options: use a vaccine patch at home, use a vaccine 
patch with a healthcare worker nearby, have a healthcare worker apply a patch to you, 
have a healthcare worker give you an injection.  For five participants for whom this 
information was unavailable, preferred method was imputed by taking the method with 
the maximum willingness-to-pay. 
 
A.3.4.10 Behavioral Questions Based on the Theory of Reasoned Action 
 Participants responded to questions based on the theory of reasoned action 
shown in Table A.2, with all items measured on a 5-point Likert scale.  
  
 109 
Table A.2 Questions based on the Theory of Reasoned Action 
 
Item 
Important people in my life will approve if I 
choose a vaccine patch instead of an injection. 
My family will think it's a good idea if I choose 
a vaccine patch instead of an injection. 
My friends will approve if I choose a vaccine 
patch instead of an injection. 
Important people in my life would suggest that I 
get a vaccine patch instead of an injection. 
My doctor will approve if I choose a vaccine 
patch instead of an injection. 
I think that vaccine patches are an improvement 
over injections. 
Compared to injections, vaccine patches have 
benefits that are important to me. 
I prefer a vaccine patch over an injection. 
Compared to vaccine patches, injections have 
drawbacks that matter to me. 
I like vaccine patches more than injections. 
Putting on a vaccine patch will be less painful 
than getting an injection. 
A vaccine patch will lead to less bleeding than 
an injection. 
A vaccine patch will lead to less skin damage 
compared to an injection. 
A vaccine patch will lead to less risk of 
infection compared to an injection. 
I think a vaccine patch could offer as much 
protection against the flu as an injected vaccine. 
Putting a vaccine patch on my arm at home is 
[less safe, as safe, safer] compared to an 
injection from a nurse or doctor. 
A vaccine patch will be more convenient for me 
than an injection. 
Overall, vaccine patches will help me save time 
compared to injections. 
It will help me if the flu vaccine is available in 
more locations. 
Vaccine patches are easy to use. 
I can easily tell if I put a vaccine patch onto my 
arm the right way. 
The vaccine patch can administer flu vaccine 
reliably. 
 
   
 110 
A.3.5 Acceptance Analysis 
A.3.5.1 Excluding Self-Administration 
 We used the stated willingness-to-pay data to define a maximum price for each 
participant where they would prefer a microneedle patch administered by a healthcare 
worker over an intramuscular injection or no vaccination.  For participants who did not 
accept the microneedle patch at any price, we arbitrarily defined their maximum 
acceptable price for at $-1000. 
Participants who normally intend vaccination and had a maximum acceptable 
price greater than or equal to their estimated intramuscular injection price were assumed 
to choose microneedle patches if both options were available at the same price.  The 
remainder of participants who normally intend vaccination were assumed to choose 
intramuscular injection.   
In the same way, participants who do not normally intend vaccination were 
binned into those who would accept a microneedle patch and those who would remain 
unvaccinated if a microneedle patch was available at the same price as an intramuscular 
injection. See Figure 5.3A for a pie chart showing how participants fell into each 
category. 
This analysis could be repeated for scenarios where the microneedle patch would 





A.3.5.1 Including Self-Administration 
 To analyze acceptance if self-administration was available, we relied on each 
participant’s chosen, preferred method.  The approach was similar to the approach section 
A.3.5.1, but the maximum price for each participant was based on their preferred method.  
The pie chart in Figure 5.3B includes self-administration options as separate categories 
and illustrates that several people who accepted microneedle patches without self-
administration would prefer a self-administered patches if they were available. 
 
A.3.6 Economic Analysis 
A quantitative economic analysis was conducted using the acceptability data.  The 
purpose of this economic analysis was the compare hypothetical scenarios with the 
introduction of microneedle patch or a self-administered microneedle patch to the current 
influenza vaccination program in the United States.  Several outcome measures were 
used for comparison.  The acceptability data from the stated willingness-to-pay 
questionnaire was the primary data source for the economic analysis.   
The analysis was a prospective analysis from the healthcare payer’s perspective 
[133].  It included four key components: 1) acceptance of vaccines based on current 
national data or the willingness-to-pay questionnaire, 2) vaccine dose costs and 
administration costs for influenza vaccination, 3) influenza illness rates (including 
hospitalization rates and deaths), and 4) vaccine effectiveness.  Outcome measures 
included coverage improvements, reduction in number of influenza cases, reductions in 
hospitalizations, reductions in deaths, comparisons of costs to improve coverage, and 
percent changes in overall vaccination program costs. 
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A general framework for the economic analysis is shown in Figure A.8, followed 
by a walk-through of a sample calculation. 
 
 
Figure A.8 General Framework for Economic Analysis 
 
A.3.6.1 Sample Calculation  
 This section includes a sample confidence interval calculation for the reduction in 
number of cases after introducing a “high-protection” microneedle patch.  The economic 
analysis itself and the calculations for this sample calculation were performed in 
MATLAB.  Most equations shown in this section use the MATLAB language.  The first 
step is to estimate the number of cases of influenza that occur with the current 
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immunization program.  The current coverage level was drawn randomly from the 
distribution shown in Table 5.3. 
 
baseline_coverage = normrnd(0.455,0.025*0.455);    Eq. A.26 
 
 The number of people vaccinated before the introduction of microneedles can be 
calculated using the coverage rate and a population basis size (194 million adults age 18-
64 based on the 2010 U.S. Census). 
 
Nvax_IM_before = baseline_coverage*basis;    Eq. A.27 
 
 The number of influenza cases that occur before the introduction of microneedles 
depends on the vaccine effectiveness and the influenza attack rate.  All vaccinations in 
this model were assumed to have the vaccine effectiveness given in Table 5.3.  The 
vaccine effectiveness, influenza attack rate, and several other parameters were defined 
using a triangular distribution.  For a random number from a 0-1 uniform distribution, U, 
a random number from a triangular distribution (with minimum, maximum, and mode of 









, *( )*( )randT a U b a c a        Eq. A.28 
Else, (1 )*( )*( )randT b U b a b c          Eq. A.29 
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 Given a random draw for vaccine effectiveness, IM_vax_effectiveness, and a 
random draw for influenza attack rate, the number of influenza cases expected before the 
introduction of microneedles is: 
 
cases_before = (basis - Nvax_IM_before*IM_vax_effectiveness) 
*influenza_attack_rate;      Eq. A.30 
 
 Calculating the number of cases expected for a “high-protection” microneedle 
patch involves estimating the improvement in coverage expected for this scenario and 
modifying the vaccine effectiveness.  The coverage is estimated using resampled data and 
the techniques described in section A.3.5.1.  The subset of participants who normal 
intend vaccination is resampled (a.k.a. bootstrapped) using the randsample function in 
MATLAB.  Each resampling yields a number of participants who would switch from 
intramuscular injection to the microneedle patch (Nvax_IM_to_HCW_MN).  Similarly, 
resampling the participants who do not intend vaccination yields a number of participants 
who would switch from no vaccination to receiving a vaccine patch 
(Nvax_NO_to_HCW_MN).  The number of people choosing each method was defined 
as: 
 
Nvax_IM_after = Nvax_IM_before - Nvax_IM_to_HCW_MN;  Eq. A.31 
Nvax_MN_after = Nvax_IM_to_HCW_MN + Nvax_NO_to_HCW_MN; Eq. A.32 
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 For the “high-protection” scenarios, it was assumed the microneedle patch had a 
higher vaccine effectiveness, 50% closer to 100% effectiveness than the standard 
vaccine. 
 
MN_vax_effectiveness = IM_vax_effectiveness  
+ .5*(1-IM_vax_effectiveness);     Eq. A.33 
 
 The number of cases expected after the introduction of a microneedle patch could 
then be calculated as: 
 
cases_after = (basis - Nvax_IM_after*IM_vax_effectiveness - 
Nvax_MN_after*MN_vax_effectiveness)*influenza_attack_rate;  Eq. A.34 
 
 The difference in the number of cases was then calculated as cases_after – 
cases_before.  This calculation represented a single iteration of the model for a single 
output measure.  Because the model relied on uncertain inputs from normal and triangular 
distributions as well as resampling of data, multiple iterations were used to examine 
prospective variability in the outcome measures.  This model used 100,000 iterations to 
force the median of separate model runs to differ by less than 5%.  With 100,000 
iterations, a median and 95% confidence interval (values 2,500 and 97,500 in a sorted 




A.3.7 Theory of Reasoned Action Analysis 
In addition to the selected demographic and behavioral correlates, the 
questionnaire included items designed to measure psychosocial indicators of microneedle 
acceptability. New scale items were developed based on previous quantitative and 
qualitative research findings, literature review, and vaccine clinical trial and community 
experience. [1-4]  In addition, psychosocial items were developed for most of the 
domains based on recommendations by behavioral theorists, guided by the Theory of 
Reasoned Action and Integrated Behavioral Models [5-9]. A team of investigators with 
expertise in  behavioral researcher and biomedical engineering reviewed the instrument 
for adequacy of the measures. 
 The following briefly describes four scale measures developed specifically to 
assess immunization issues. Each scale item was measured by a 5-point Likert scale (1-
strongly disagree to 5-strongly agree), designed to assign meaningful values to an 
underlying continuum of ratings [10]. These scales were added to the multivariate models 
as scores based on the average of the component answers of the scale.  
Microneedle Use  Attitudes. Six items comprised this scale. Four  items assessed 
the benefit of using a vaccine patch compared to existing intradermal injection methods.  
These included items, “I think that vaccine patches are an improvement over injections,” 
“I prefer a vaccine patch over an injection,” “Compared to injections, vaccine patches 
have benefits that are important to me,” and “I like vaccine patches more than injections.” 
In addition, one item compared perceived pain associated with patch use compared to 
injections. It was phrased, “Putting on a vaccine patch will be less painful than getting an 
injection.” Finally, one item examined participants’ attitudes toward injection drawbacks. 
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The statement read “Compared to vaccine patches, injections have drawbacks that matter 
to me.” 
Behavioral Beliefs. In this seven item scale, we evaluated the extent to which 
people considered the microneedle innovation to be a reliable and protective mechanism 
against influenza via two items. They stated, “The vaccine patch can administer flu 
vaccine reliably” and “I think a vaccine patch could offer as much protection against the 
flu as an injected vaccine.” Additionally, in four items we explored beliefs associated 
with its  perceived convenience, time savings, self-administration method, and future 
availability. Participants expressed their level of agreement with these items stating 
“Putting a vaccine patch on my arm at home is [less safe, as safe, safer] compared to an 
injection from nurse or doctor,” “A vaccine patch will be more convenient for me than an 
injection,” “Overall, vaccine patches will help me save time compared to injections,” and 
“Vaccine patches are easy to use.” The last scale item explore behavioral beliefs 
associated with ease of use. The statement indicated “I can easily tell if I put a vaccine 
patch on my arm the right way.” 
Normative Approval. Previous studies examining vaccine acceptability have 
accounted for normative expectations in overall models [11, 12]. Given the extent of 
evidence suggesting the importance of normative approval as a vaccine decision-making 
facilitator [2, 4, 13], we developed five items that specifically assessed the expressed or 
perceived approval of doctors, family, work colleagues, and friends in deciding to use 
microneedle devices in the future. Questions included “My family will think it’s a good 
idea if I choose a vaccine patch instead of an injection,” “Important people in my life will 
approve if I choose a vaccine patch instead of an injection,” “My friends will approve if I 
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choose a vaccine patch instead of an injection,” “My doctor will approve if I choose a 
vaccine patch instead of an injection,” and “Important people in my life would suggest 
that I get a vaccine patch instead of an injection.”  
Outcome Evaluation. Issues related to side effects resulting from microneedle use 
were measured by three items included in this domain. One statement explored 
participants’ perceived likelihood of experiencing bleeding as follows: “A vaccine patch 
will lead to less bleeding than an injection.” Another examined perceived skin damage 
occurring as a result of its application. It indicated “A vaccine patch will lead to less skin 
damage compared to an injection.” Finally, one item inquired about potential for 
infection with the statement “A vaccine patch will lead to less risk of infection compared 
to an injection.” 
 
A.3.7.1 Statistical Analysis 
SAS version 9.3 was used for analyses (SAS Institute Inc, Cary, NC, USA). 
Descriptive statistics and cross-tabulations were generated for variables of interest. 
Bivariate correlations were also generated to explore key relationships. An exploratory 
factor analysis was conducted using SPSS version 20.0 and resulting scale reliability 
estimates were generated. The lower bound for item extraction was determined based on 
resulting values of ≥0.50. We determined a Cronbach alpha reliability estimate of  ≥0.70 
would support reliability of each subscale [14]. Multivariate logistic regression models 
were used to analyze the independent contributions of variables. Significant independent 
predictors of outcomes were assessed at α=0.05 levels.  
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A.3.7.2 Factor Analysis and Internal Consistencies 
With 21 questionnaire items, we conducted an exploratory principal components 
factor analysis using Varimax rotation method that resulted in a 4-factor solution 
(65.54% cumulative variance). The first extracted factor, “Microneedle Attitudes,” 
comprised the largest portion of the variance (37.23%) with an initial Eigenvalue total 
sum of square loading totaling 7.82.  Following rotation, its contribution to the 
cumulative variance resulted in 20.39% of the total variance value of 65.54%. The 
“Behavioral Beliefs” component added the second largest contribution to the overall 
variance with a final rotated value of 18.52% of the variance thereby resulting in 38.91% 
with consideration of the attitudinal component. “Subjective norms” provided an 
additional 14.82% of the total variance as the third factor and “Outcome Evaluations” 
contributed the final 11.82% of the cumulative percentage accounted for by these factors 
(65.43%). The internal consistencies achieved on the four scales demonstrated a high 
level of reliability. “Microneedle Attitudes” resulted in the highest alpha score of 0.904. 
This was followed by “Normative Approval” (α = 0.845) and “Behavioral Beliefs” (α = 
0.845) and “Outcome Evaluations” (α = 0.806).  
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FORMS USED IN HUMAN STUDIES 
 
 For the human studies described in Chapters 4 and 5, this appendix contains 
protocols, consent forms, assent forms, and data sheets. 
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